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ABSTRACT
The metabolic syndrome (MetS) is a constellation of metabolic abnormalities including central
obesity, insulin resistance, elevated glucose concentration, dyslipidemia and elevated blood
pressure. More than 25% of Finnish adults have MetS. MetS can likely be prevented by diet and
exercise. For example, a high intake of whole grain foods has been inversely associated with MetS
and T2DM. However, there is still very little information on the effects of diet in persons with
MetS.
  The effects of two diets differing in cereal foods (rye bread and oat-wheat bread) producing low
and high insulin responses in persons with MetS were investigated. Specifically, the relation of
glucose metabolism and insulin action to the gene expression of abdominal subcutaneous adipose
tissue (SAT) was studied. Different postprandial insulin responses were hypothesized to be
reflected in the gene expression of SAT. The two interventions produced different gene expression
profiles in SAT compared with baseline. Moreover, the interventions modulated the inflammation
status in individuals with MetS. Genes regulating insulin signaling and apoptosis were down-
regulated during the low insulin response diet, and genes related mainly to metabolic stress were
up-regulated during the high insulin response diet. One of the genes that down-regulated during
the low insulin response diet was insulin-like growth factor binding protein 5 (IGFBP5). The
genetic variation of IGFBP5 was studied in two independent populations, the Finnish Diabetes
Prevention Study and Metabolic Syndrome in Men. Three IGFBP5 markers were significantly
associated with circulating adiponectin concentrations in men with impairments in glucose
tolerance. Moreover, IGFBP5 gene expression in SAT was correlated with ADIPOQ gene
expression in all subjects and in women. The role of IGFBP5 in adipocyte function was further
examined in vitro. The data provided indicates that IGFBP5 has an active role in adipocyte biology.
   In conclusion, the diets with different insulin responses modulated the gene expression profile in
SAT. The changes seen at the transcriptional level of AT may predict effects at the whole-body
level. Moreover, the study demonstrates that the microarray study combined with a diet
intervention is an effective hypothesis generator to find new candidate genes related to MetS.
National Library of Medicine Classification: WK 820, QU 75, WB 431, QU 475, QU 500
Medical Subject Headings: Metabolic Syndrome X; Dietary Carbohydrates; Cereals; Insulin; Gene
Expression Profiling; Genetic Variation; Adipose Tissue; Insulin-Like Growth Factor Binding
Protein 5; Microarray Analysis; Humans
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TIIVISTELM
Metabolinen oireyhtymä on monisyinen riskitekijäkasauma, jonka tunnusomaisia piirteitä ovat
keskivartalolihavuus, insuliiniresistenssi, kohonnut veren glukoosipitoisuus, dyslipidemia sekä
kohonnut verenpaine. Suomessa metabolisen oireyhtymän esiintyvyys aikuisväestössä on yli 25%,
mutta riskiä voidaan alentaa oikean ruokavalion ja liikunnan avulla. Epidemiologisten
tutkimusten mukaan erityisesti täysjyväviljatuotteiden ja viljan ravintokuidun tiedetään
vähentävän riskiä metaboliseen oireyhtymän osatekijöihin. Näyttöä edullisten vaikutusten
molekyylitason vaikutusmekanismeista ei kuitenkaan ole.
Tässä tutkimuksessa selvitettiin kahden erilaisen runsaasti täysjyväviljaa (ruisleipä ja kaura-
vehnäleipä) sisältävän ruokavalion pitkäaikaisvaikutuksia rasvakudoksen geenien ilmentymiseen
henkilöillä, joilla oli metabolisen oireyhtymän piirteitä. Viljatuotteiden aterianjälkeiset
insuliinivasteet poikkesivat toisistaan merkitsevästi ja tämän oletettiin vaikuttavan rasvakudoksen
geenien ilmentymisprofiili . Tutkimuksessa tunnistettiinkin kaksi erilaista geenien
ilmentymisprofiilia. Insuliinin signaalireittiin ja solukuolemaan liittyvien geenien ilmeneminen
väheni matalan insuliinivasteen aiheuttavan ruokavalion (ruisleipä ja pasta) aikana.  Metaboliseen
stressiin liittyvien geenien ilmeneminen puolestaan lisääntyi korkean insuliinivasteen aiheuttavan
ruokavalion aikana (kaura-vehnäleipä ja peruna). Lisäksi verestä mitatut tulehdustekijäprofiilit
olivat erilaiset ryhmien välillä. Yksi geeneistä, jonka ilmeneminen väheni matalan insuliinivasteen
aiheuttavan ruokavalion aikana, oli IGFBP5 (insuliinin kaltaisen kasvutekijän sitojaproteiini 5) -
geeni. Tämän geenin geenivariaation yhteyttä metabolisen oireyhtymään tutkittiin Suomalaisessa
Diabeteksen Ehkäisytutkimuksessa sekä Metabolinen Oireyhtymä Miehissä-tutkimuksessa.
Kolmen IGFBP5:n geenivariaation todettiin olevan yhteydessä veren adiponektiinipitoisuuksiin
miehillä, joilla oli heikentynyt glukoosinsieto. Lisäksi IGFBP5-geenin ilmeneminen korreloi
positiivisesti adiponektiini-geenin ilmenemiseen kaikilla koehenkilöillä sekä erityisesti naisilla.
IGFBP5-geenin roolia selvitettiin edelleen rasvasoluissa in vitro ja tulokset osoittivat, että geenillä
on aktiivinen rooli myös rasvasolun biologiassa.
Yhteenvetona voidaan todeta, että erilaisen insuliinivasteen omaavat ruokavaliot aiheuttivat
toisistaan poikkeavia muutoksia rasvakudoksen geenien ilmentymisprofiilissa. Rasvakudoksessa
havaitut geenien ilmenemisen muutokset voivat täten ennakoida tapahtumia myös koko elimistön
tasolla. Lisäksi tutkimus osoittaa kliinisen interventiotutkimuksen ja geenisirumenetelmän
yhdistelmän olevan tehokas tapa löytää geenejä, jotka voivat olla yhteydessä metaboliseen
oireyhtymään.
Yleinen suomalainen asiasanasto (YSA): metabolinen oireyhtymä; hiilihydraatit; viljavalmisteet;
insuliini; glukoosi; genomiikka; rasvakudos; tulehdus;
Ä
in
VIII
“The wise speak only of what they know”
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1 INTRODUCTION
The metabolic syndrome (MetS) is defined as a constellation of metabolic abnormalities including
insulin resistance, glucose intolerance, central obesity, dyslipidemia and elevated blood pressure
(1). The pathogenesis of metabolic syndrome is not well understood, but lifestyle, including diet
and physical activity together with genetic factors clearly interact in its development (2). MetS can
lead to type 2 diabetes (T2DM). In contrast to advanced T2DM, MetS may be a reversible condition
if addressed early enough (3). Thus, studies focusing on early detection of MetS are important.
Cereal foods are a major source of energy intake (mainly in form of starch) in the human diet
worldwide. Based on epidemiological evidence, whole grain food consumption has been suggested
to have many health-promoting effects, including protection from MetS (4). However, currently
most cereal foods in Western countries are based on refined flour.
The genetic basis of complex diseases can be studied with various strategies, such as genome
wide association studies, candidate gene approach, genome wide expression studies or other
expression studies. Gene expression profiling using microarrays is a powerful tool for finding genes
and pathways that modulate the development of conditions such as MetS (5). Prior to this study,
microarray technology had not been applied to study the effects cereal diets on gene expression of
SAT in dietary interventions in humans.
In this study, the cereal study diets were tailored to generate different postprandial insulin
responses. The study was undertaken to detect genetic and metabolic changes induced by these diets
by applying modern nutrigenomics and molecular biological technology. Specifically, the role of
the diets in persons with MetS was investigated 1) by studying the postprandial responses 2) by
investigating the serum inflammation markers 3) by examining the global gene expression 4) by
studying the association of genetic variations of IGFBP5 (gene responding to low insulin response
diet found in earlier study) with markers of MetS and 5) by studying the role of IGFBP5 in vitro in
adipocyte biology.
2
32 REVIEW OF LITERATURE
2.1 The Metabolic Syndrome
2.1.1 Definition
MetS is a combination of disturbances (visceral obesity, insulin resistannce, dyslipidemia, glucose
intolerance and hypertension) that increase the risk of cardiovascular disease and T2DM (6). The
first constellation of the MetS was made by Swedish physician Kylin clustering hypertension,
hyperglycemia and gout in the 1920´s. In 1947, Vague concluded that upper body adiposity was
commonly associated with T2DM and cardiovascular disease (1). In his Banting Award lecture in
1988, Gerald M. Reaven proposed insulin resistance as the underlying factor and named the
constellation of abnormalities as Syndrome X (7). Surprisingly, he omitted abdominal obesity, now
seen by many as an essential component, from the definition (1). Lemieux et al. (8) suggested
visceral obesity and hypertriglyceridemia, which they termed as the hypertriglyceridemic waist
phenotype, to be the central components of MetS. Today MetS is considered to be a condition
characterized by, abdominal obesity, insulin resistance, dyslipidemia and hypertension (9,10), but
still the diagnostic criteria and the concept of MetS is under debate (11-13).
  The  importance  of  defining  MetS  is  that  it  helps  to  identify  individuals  at  a  high  risk  of
developing both T2DM and CVD. Over the years, several expert groups have attempted to produce
solid diagnostic criteria for MetS. There are three major definitions for metabolic syndrome: The
first was provided in 1999 by World Health Organization (WHO) (14,15), in the same year
European Group for the Study of Insulin Resistance (EGIR) produced a modification of the WHO
criteria (16) and a different approach came from US National Cholesterol Education Program
(NCEP ATPIII) in 2001 (17). The NCEP:ATP III produced less glucocentric view than definitions
of WHO and EGIR. In 2004, The International Diabetes Federation (IDF) attempted to make a
consensus statement grouping all definitions in to one practical definition adding also different
standards for waist measurement for different ethnic groups (18). The definitions are presented in
detail in the Table 1.  In 2004, the American Heart Association proposed small changes to the
NCEP definition (19). In addition, there are various other criteria including that of Association of
American  Clinical  Endocrinologists  (20).  All  of  these  definitions  agree  on  the  essential
components: glucose intolerance, obesity, hypertension and dyslipidemia, but they still differ in
detail. There is still no consensus on the appropriate definition, or even on the clinical importance of
diagnosing MetS (21-23).
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52.1.2 Prevalence
The prevalence of MetS has increased significantly over the past decade among both adults and
adolescents (24). However, the comparison of published prevalence is difficult due to different
definitions and study designs (25,26). An estimated >47 million adults and >2 million adolescents
currently  have  MetS  in  the  USA.  According  to  NCEP:ATP  III  definition  the  prevalence  of  the
metabolic syndrome in U.S. adults > 20 years of age was 23.7%. The prevalence is increasing with
age, reaching over 40% for those of over 60 years (24). The prevalence of metabolic syndrome
seems to be highly age-dependent (1). However, along with increasing rates of obesity in young and
adolescents MetS is becoming more prevalent in childhood (27). In Finland, the prevalence of MetS
is 38.8% in men and 22.2% in women according the WHO criteria (28). The prevalence of the MetS
increases with deterioration in glucose regulation in both sexes. In the Finnish Diabetes Prevention
Study  (DPS), the MetS was present in 78.4% of the men and 72.2% of the women with IGT (28).
2.1.3 Clinical features of MetS
Obesity may lead to insulin resistance, glucose intolerance, metabolic syndrome and eventually
T2DM  (Figure  1). This is called the progressive phenotype hypothesis. In this hypothesis, the
excess of energy intake leads to weight gain and low-grade inflammation. This in turn results in
abdominal obesity and insulin resistance, which leads to MetS and eventually to full-blown T2DM
in genetically susceptible individuals (2).  Gerald M. Reaven has stated that the defect in insulin
action plays a fundamental role in the development of the metabolic syndrome (23).
6Figure 1. The progressive phenotype hypothesis. The relation of obesity and insulin resistance to
the metabolic syndrome and T2DM. Adapted and modified from Roche et al. 2005 (2).
2.1.3.1 Obesity
Obesity is a condition in which the natural energy reserve, stored in the adipose tissue, exceeds
healthy limits (29). It is typically assessed by body mass index (BMI), which is calculated as body
weight (kg) divided by height squared (m2). In adults overweight is defined as BMI 25-29.9kg/m2
and obesity as BMI30kg/m2 (29). The excess of central adiposity is considered to be a risk factor
for insulin resistance, glucose intolerance, dyslipidemia and elevated blood pressure (30).
Obesity is a well-recognized epidemic in Westernized cultures (31). The WHO has stated that
approximately 1.6 billion adults were overweight and at least 400 million obese in the year 2005
(32). Moreover, they project that by the year 2015 there will be 2.3 billion overweight and 700
million obese adults in the world (32).  Some experts have predicted that the current generation of
children is likely to have shorter life expectancies than their parents because  of  obesity  (33).  In
7Finland, like in other countries, the prevalence of obesity has increased (34). In fact, Finnish are the
most obese population in Scandinavia (29). The national FINRISK 2007 survey showed that 22.1%
of men and 23.4% of women were obese. Moreover, 48.5% of men and 33.3% of women were
overweight (FINRISK 2007). Also abdominal obesity has increased independently of BMI in the
Finnish population (34). The mean BMI in men has steadily increased since the 1970s. Based on the
FINRISK 2007 survey the increase in obesity is decelerating. Whether the rate of obesity will reach
plateau remains to be seen in the 2012 FINRISK survey.
All four definitions of MetS include abdominal obesity in their definitions (Table 1). Obesity is
defined as a key condition that predisposes to the development of MetS (35). Obese individuals
usually have elevated insulin levels, and they are usually insulin resistant (36). However, it should
be remembered that normal weight individuals may also have abdominal obesity and insulin
resistance (37).
2.1.3.2 Insulin resistance
Insulin resistance (IR) is defined as a reduced sensitivity of tissues to the action of insulin (10). In
an insulin-resistant person, normal levels of insulin do not have the same glucose lowering effect as
in a healthy person (38). The defect in insulin action increases glucose production by the liver and
kidney and decreases glucose uptake in insulin-sensitive tissues (i.e. muscle and adipose tissue) (1).
If insulin action is defected, insulin secretion or clearance must be modified to sustain normal
glucose homeostasis. The pancreas compensates for higher glucose concentrations in an insulin-
resistant individual by releasing more insulin (39). When pancreas fails to produce sufficient
insulin, T2DM becomes evident.
The exact cause of insulin resistance is still unknown. However, IR can be a result from high
levels of circulating fatty acids i.e. obesity-induced insulin resistance (37-39) (Figure  2). An
enlarged fat mass leads to increasing lipolysis in the whole body level and thus elevates the
circulating FFAs (40-42). The release of FFAs can block the insulin-signaling pathways in muscle
and adipose tissue. Moreover, an excess of FFAs can cause IR in ȕ-cells, which when prolonged
exposure may impair insulin secretion (1). Increases in FFA flux have been shown in numerous
models to impair hepatic insulin action (43). This mechanism is called lipotoxicity (44). Elevation
of FFAs can rapidly cause insulin resistance (45,46), and both hyperinsulinemia and IR generally
precede T2DM (9,47,48).
8Figure 2. Obesity-induced insulin resistance. Plasma free fatty acid (FFA) levels are elevated in
obesity. FFAs cause insulin resistance in target organs of insulin (skeletal muscle and liver). In
skeletal muscle, glucose uptake decreases and in liver, glucose production increases. Initially, the
pancreatic ȕ-cells compensate for the increase in circulating glucose by producing more insulin.
With time, the ȕ-cells will fail to secrete sufficiently large amounts of insulin, which leads to
impaired glucose tolerance and eventually to T2DM. Modified from Hajer et al. (49).
2.1.3.3 Glucose intolerance and insulin action in MetS
The WHO classifies the slight increase in plasma glucose between normal and diabetic states as
impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). The diagnostic criteria are
based on the 1997 Expert Committee report and with small revisions done in 2003 are as follows:
IGT  is  fasting  plasma  glucose  concentration  <7.0  mmol/L  and  2  hours  after  75  g  of  glucose
ingestion 7.8-11.0 mmol/L. The corresponding fasting glucose concentration in IFG is 5.6-6.9
mmol/L (50). IGT may precede T2DM and is also a risk factor for mortality (51). The analysis of
six prospective studies found that fasting and post-load glucose concentrations and BMI measured
9at the time of IGT recognition were the most consistent and strongest predictors of the progression
from IGT to T2DM  (52).
2.1.3.4 Dyslipidemia and hypertension
Lipid abnormalities often present in individuals with MetS are hypertriglyceridemia, low HDL
cholesterol  and  (small  and  dense)  LDL  particle  size  (53).  Low  fasting  serum  HDL  and
hypertriglyceridemia are associated with other components of MetS. Apolipoproteins A1 and B, and
HDL subfractions are also associated with MetS (10,54,55). The reduction of HDL cholesterol is a
consequence of changes in HDL composition and metabolism (56). In the normal physiological
condition insulin rather inhibits than increases the secretion of VLDL in to the circulation (57). An
increase in FFA flux to the liver also increases the production of very low-density lipoprotein
(VLDL) (58). Elevated blood pressure is a typical component of the MetS and hypertension is more
frequent in subjects with either insulin resistance or obesity (1). Studies have demonstrated that
even modest weight gain can increase blood pressure (59).
2.1.4 Genetic determinants of MetS
The genetic basis of features of MetS has been elucidated in many studies. A high heritability has
been reported for fasting glucose, insulin, triglyceride and HDL cholesterol (60,61). There is also a
marked difference in the prevalence of MetS and T2DM among various ethnic groups (62). Rich et
al. (63) have shown that in a European population siblings of family members with T2DM have a
3.5-4 times higher risk to develop T2DM than the average population. In a twin study, Poulsen et al.
(64) studied the role of genetic vs. environmental factors for the development of MetS. The study
demonstrated that a core complex including hyperinsulinemia, obesity, hypertriglyceridemia and
low HDL-cholesterol was more pronounced in monozygotic twins than dizygotic twins. However,
they detected only weak associations with glucose concentrations and blood pressure levels. This
might indicate that these factors are more strongly modulated by environmental than genetic factors.
Poulsen et al. suggested that coupled with genetic susceptibility the current trend in food choices
and physical inactivity has led to a dramatic rise in the incidence of MetS (65).
There are multiple ways how genes may influence the development of MetS (66).  The individual
components of MetS have their own genetic basis, for which candidate genes have been identified.
These associations may predispose to the development of MetS. For example, visceral obesity has
been associated with sequence variation of ADIPOQ, which encodes adiponectin (67).
Hypertension has been associated with variations in angiotensinogen (AGT) (68), whereas plasma
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lipid concentrations have been associated with variations in apolipoproteins E and C-III,
respectively (69). Variants associated with the individual components could therefore underlie
associations with the entire MetS. Identification of genetic component underlying the MetS has
been  challenging  and  only  few associations  have  been  reported  so  far.  However,  the  associations
found are quite weak and lack repeatability across other studies. Positive associations that have
been replicated more than in one study sample are found in with common SNPs in apolipoprotein
C-III (70,71) and PPARȖ (72,73). Genetic studies that show a positive association with MetS
defined by the NCEP ATP III have been reported for common SNPs in the ȕ2-adrenergic receptor
(74), AGT (women only) (70), LDL-receptor (75), lamin A/C, a nuclear envelope protein (rare
mutation) (76), low density lipoprotein receptor-related protein-associated protein (women only)
(75), nitric oxide synthase 3 (hypertensive only) (77) and MetS defined by the WHO in IL6 (78).
Also, conflicting associations have been reported between MetS and SNPs in genes encoding
angiotensinogen-I-converting enzyme (79,80), fatty-acid binding protein 2 (71,81) and the G
protein ȕ3 subunit (70,82).
The genome-wide association (GWA) studies have been shown to be more potent for identifying
common susceptibility variants than the traditional candidate gene approach. Thus, several large
studies of traits relevant to MetS, T2DM and CAD have been reported. The studies have identified a
number  of  novel  genes  and  loci.  In  addition  to  novel  findings,  the  GWA  studies  also  confirmed
number of genes identified earlier using candidate gene approach. Two common variants that affect
fasting  glucose  levels  are  glucokinase  (hexokinase  4)  regulator  (GCKR)  and  the  genomic  region
containing glucose -6-phosphate, catalytic 2 abd ATP-binding cassette, sub-family B, member 11
(83,84). Two variants affect adiposity, namely FTO and melanocortin 4 receptor (85,86), many
variants are in the T2DM loci (87) and many are in HDL and LDL-cholesterol loci (88). However,
none of the gene variants affect all traits of MetS.
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2.1.5 Environmental factors and nutritional management of MetS
In addition to genetic determinants, the underlying factors of MetS are environmental.  As stated
earlier, people with MetS are at increased risk of coronary heart disease, other vascular diseases
(e.g., stroke and peripheral vascular disease) and T2DM. Long-term lifestyle intervention studies
have shown that even the modest changes in lifestyle can prevent or delay the appearance of T2DM
in persons with IGT (89-91).
The first-line of intervention for the MetS involves lifestyle modification, including change in
weight management, diet, and physical activity (19). Physical activity and weight maintenance are
also recommended to prevent the development of MetS (19).  It has been demonstrated that after the
energy restriction major improvements was seen in insulin resistance and in glycemic control before
there was any significant weight loss (92,93). Long-term adherence to these changes is essential for
the successful management of this chronic condition. Results demonstrate that among participants
who had MetS at baseline, 38% no longer had it after a mean 3.2 years of follow-up of lifestyle
intervention (3). This illustrates that the metabolic syndrome, in contrast to advanced T2DM, may
be a reversible condition if addressed early enough.
To manage MetS, American Heart Association (AHA) recommends certain lifestyle changes (94).
These changes include weight control, increased physical activity, and a diet designed to reduce risk
for cardiovascular disease (94). The AHA 2006 Diet and Lifestyle Recommendations are presented
in Table 2. By reducing caloric intake while maintaining a moderate-fat diet and increasing physical
activity to achieve weight loss improve insulin resistance and the concomitant metabolic disorders
(94). Dietary management is considered to be the cornerstone in the treatment of T2DM. Standard
dietary advice for patients with impaired glucose tolerance in general includes whole-grain cereals,
low-fat dairy products, vegetables, fruits, legumes, oily fish and refined fats rich in MUFAs and low
in SFAs (95). However, according to recent Cochrane review high quality data on the efficicacy of
dietary treatment of T2DM are lacking (96).
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Table 2. AHA 2006 Diet and lifestyle recommendations for cardiovascular disease risk reduction.
1. Balance calorie intake and physical activity to achieve or maintain a healthy body
weight.
2. Consume a diet rich in vegetables and fruits.
3. Choose whole grain, high-fiber foods.
4. Consume fish, especially oily fish, at least twice a week.
5. Limit your intake of saturated fat to <7% of energy, trans fat to <1% of energy, and
cholesterol to <300 mg per day by
             -choosing lean meats and vegetable alternatives;
             -selecting fat-free (skim), 1%-fat, and low-fat dairy products; and
             -minimizing intake of partially hydrogenated fats.
6. Minimize your intake of beverages and foods with added sugars.
7.  Choose and prepare foods with little or no salt.
8. If you consume alcohol, do so in moderation.
9. When you eat food that is prepared outside of the home, follow the AHA Diet and
Lifestyle Recommendations.
The quantity and quality of the carbohydrate have been associated with MetS. Refined
carbohydrates with high GI, fiber depleted starches and sugars in soft drinks have all been linked to
the MetS (97,98). Moreover, there is evidence that the rate of absorption may influence the
glycemic and insulinemic response (99). Low GI diets may, therefore, be associated with protection
of  components  of  MetS.  Furthermore,  AHA  recommends  consuming  at  least  half  of  grain  intake
from whole-grains.  In epidemiological studies, insoluble fiber has been associated with decreased
CVD risk and slower progression of CVD and T2DM in high-risk individuals (94).
 In the light of very recent evidence, a diet based on hunter-gatherer type diet (i.e. Paleolithic diet)
may be beneficial in treatment of MetS and T2DM (100-103). A paleolithic diet composed of lean
meat, fruits, vegetables and nuts, excluding foods such as cereal grains, dairy products and legumes
improves glucose tolerance even more than Mediterranean type diet (103). The improvement of
glucose tolerance was independent of energy intake and macronutrient composition (103).
Moreover, there is a recent randomized cross-over pilot study concerning the Paleolithic diet
showing improvements in glycemic control  and reduction HbA1c, triglycerides, diastolic blood
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pressure, weight and waist circumference in patients with T2DM (101). Frassetto and co-workers
(102) have recently shown that a Paleolithic-type diet improves blood pressure and glucose
tolerance, decreases insulin secretion, increases insulin sensitivity and improves lipid profiles
without weight loss in healthy sedentary humans. However, in practical terms, it may be demanding
to  follow this  kind  of  diet.  It  is  clear  that  larger  scale  studies  are  still  needed  in  order  to  confirm
these results.
2.2 White adipose tissue
The primary and classical role of AT is to store and release energy and to insulate and cushion the
body (49).  Moreover, WAT is a complex, essential and highly active metabolic and endocrine
organ. In addition to adipocytes, WAT contains connective tissue matrix, nerve tissue, immune cells
and stromal-vascular fraction containing fibroblasts, endothelial cells and preadipocytes (104).
Together the components function as an integrated unit (105). WAT is separated into several
different depots, mainly visceral and subcutaneous adipose tissue, VAT and SAT, respectively
(106). The depots differ from each other in adipogenic potential and lipolytic responses. VAT has
stronger association to metabolic risks than SAT (11). WAT is playing crucial role in glucose and
lipid metabolism (107), inflammation (108), blood pressure (109) and feeding behavior (110).
Studies during past years have revealed that WAT has an important role in controlling whole body
glucose homeostasis in both normal and disease states (111). WAT also affects the metabolism of
other tissues including liver, skeletal muscle, vasculature and brain (112,113). An excess of AT
(obesity),  particularly  excess  of  VAT,  is  associated  with  insulin  resistance,  hyperglycemia,
dyslipidemia, blood pressure, proinflammatory states and prothrombosis (114). Dysfunction of AT
is involved in the development of insulin resistance, T2DM and CVD (49). Interestingly, AT
deficiency or lipodystrophy is also associated with MetS (115). Thus, it is justified to state that both
an excess and deficiency of AT may have adverse health consequences.
2.2.1 Adipokines
Adipose tissue is known to express and secrete multiple bioactive adipokines (Table 3), such as
adiponectin, leptin, visfatin and PAI-1 and cytokines including TNF-Į, IL-6 and IL-ȕ which act via
autocrine, paracrine and endocrine mechanisms (116). In addition, AT expresses numerous
receptors for hormones (insulin, glucagon, GH, GLP-1), nuclear hormones (vitamin D,
glucocorticoid), cytokines (leptin, TNF-Į, IL-6) and catecholamines (ȕ1, Į1) (117).
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Table 3. Main adipokines and their effects (49,107-110,118).
Adiponectin is mostly secreted by adipocytes, aggregates in multimeric forms, and circulates at
high concentrations in blood (119,120). It is an important autocrine/paracrine factor in adipose
tissue that modulates differentiation of preadipocytes (121). There are data suggesting that
adiponectin acts as an insulin-sensitizer and anti-atherogenic adipokine (120). Adiponectin exert
differential biologic effects with favorable metabolic effects (i.e. greater insulin sensitivity, reduced
visceral adipose mass, reduced plasma triglycerides, and increased HDL-cholesterol) (122-124).
Unlike most other adipose-derived hormones, adiponectin is down-regulated in obesity and the lack
of adiponectin has been associated with the metabolic syndrome. Plasma levels of adiponectin are
decreased in individuals with T2DM (123,125,126), obesity (127), and coronary artery
disease(128). Weight loss, however, has been shown to result in increased plasma adiponectin
levels in obesity (121). These studies emphasize the role played by adiponectin in the homeostasis
of adipose tissue and in the pathogenesis of the MetS, T2DM, and atherosclerosis.
Adipokine Effects on
Plasminogen activator inhibitor-1 fibrinolysis
Angiotensinogen blood pressure
Angiotensin blood pressure
Leptin food intake, fat mass
Tumor necrosis factor-Į inflammation
Interleukin 6 inflammation
C-reactive protein inflammation
Visfatin insulin resistance
Omentin insulin resistance
Adiponectin insulin resistance, inflammation
Resistin insulin resistance, inflammation
Cholesteryl ester transfer protein lipid metabolism
Hormone sensitive lipase lipid metabolism
Lipoprotein lipase lipid metabolism
Apelin vasodilation
Adipsin lipid metabolism
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2.2.2 Insulin signaling in white adipose tissue
Insulin is a key regulator of anabolic responses in WAT (40). A primary effect of insulin is to
stimulate glucose uptake into AT and skeletal muscle (129). Moreover, insulin stimulates FFA
uptake, inhibit lipolysis, and stimulate de novo fatty acid synthesis in adipocytes (130). In addition,
insulin modulates adipose tissue growth and differentiation (131). Insulin regulates the expression
of SREBP-1c and PPAR-Ȗ in adipocytes, both important transcription factors modulating adipose
tissue function (132).
 Binding of insulin to its receptor activates the tyrosine phosphorylation of insulin receptor and its
substrates  by  insulin  receptor  tyrosine  kinase  (133).  This  allows  association  of  IRSs  with  the
regulatory subunit of phosphoinositide 3-kinase (PI3K). PI3K activates 3-phosphoinositide-
dependent protein kinase 1 (PDK1), which activates Akt, a serine kinase. Akt in turn deactivates
glycogen synthase kinase 3 (GSK-3), leading to activation of glycogen synthase (GYS) and thus
glycogen synthesis (133). Activation of Akt also results in the translocation of GLUT4 vesicles
from their intracellular pool to the plasma membrane, where they allow uptake of glucose into the
cell (134).
 Adipose tissue accounts for about 10% of the insulin-stimulated whole body glucose uptake,
while skeletal muscle accounts for 60-70% and liver 30% (135-137). Because lipolysis and high
circulating FFA concentrations inhibit glucose uptake in other insulin-sensitive tissues, AT plays a
crucial role along with the muscle and liver tissues in the development of insulin resistance
(49,136). There are differences between the fat depots. The adipocyte signaling system of VAT
shows greater and earlier responses to insulin than SAT (131). In insulin-resistant adipocytes insulin
signaling is inhibited downstream of the insulin receptor. The phosphorylation of insulin receptor
substrate-1 occurs primarily at inhibitory serine residue instead of stimulatory tyrosine residue
(138).
 Insulin-resistant adipocytes cause increased release of FFAs (139). Insulin is the main regulator of
hormone-sensitive lipase (HSL) (140), and HSL is the rate-limiting enzyme in the lipolysis cascade
(41). Recently adipose triglyceride lipase (ATGL) has been found to be an important player in this
cascade (141). It has been observed both at the mRNA and protein levels in subcutaneous and
visceral AT that increased ATGL mRNA levels might contribute to elevated FFA mobilization
(142). Moreover, increased circulating FFA levels are shown to reduce circulating adiponectin
levels resulting in leptin resistance lead to decreased lipid oxidation in non-adipose tissues, thereby
triggering ectopic accumulation of lipids, lipotoxicity and insulin resistance (139).
 Insulin resistance in AT is associated with increased levels of stress-related hormones such as
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glucocorticoids (143). Obesity results in over expression and accumulation of inflammation-related
adipocytokines (116). Chronic nutrient overload causes an increase in adipose depots by adipocyte
hypertrophy. This adipocyte hypertrophy is a possible stress condition for the endoplasmic
reticulum (ER) that may lead to a proinflammatory state in adipose tissue (144,145). ER stress may
activate metabolic pathways that trigger insulin resistance, release macrophage chemoattractant
proteins, and in chronic inflammation, cause the death of the hypertrophic adipocyte (146).
Infiltrated macrophages in turn release inflammatory proteins, causing further recruitment of
macrophages to adipose tissue and the release of inflammatory cytokines (147).
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2.3 Whole grain foods and health
2.3.1 Definition of whole grain
Whole grains have been part of the human diet for centuries. The cereal grains consumed by human
are seeds belonging to the Gramineae family of grasses. Commonly consumed whole grains in
Western nations are derived from wheat, rice, corn, rye, oat, barley, sorghum and various millets
(148). Whole grains have three main anatomic parts: the germ, the bran and the endosperm (Figure
3). The germ and bran contain dietary fiber and the biologically active components such as protein
and  amino  acids,  essential  fatty  acids,  B  vitamins,  Vitamin  E,  minerals  and  phytochemicals.  The
endosperm of the grain consists mainly of starch and protein. Many of these nutrients and non-
nutrients are lost in the modern refining processes (149).
Figure 3. The main parts of whole grain. Modified from Marquart 2007 (4).
Traditionally,  also  the  bran  and  the  germ of  the  grains  were  eaten.  Development  of  the  modern
milling offered an easy separation method to produce endosperm flour where outer bran layer and
most of the germ were removed. While refined flour helped to provide texture and flavor in baked
products appealing to consumers, it lacked the dietary fiber and many of the vitamins, minerals and
phytochemicals (148).
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Defining the “whole grain” has been under debate. The U.S. Whole Grain Council defines whole
grains as follows: “Whole grains or foods made from them contain all the essential parts and
naturally-occurring nutrients of the entire grain seed. If the grain has been processed (e.g., cracked,
crushed, rolled, extruded, and/or cooked), the food product should deliver approximately the same
rich balance of nutrients that are found in the original grain seed (150). Several epidemiological
studies have defined the whole grain foods according Jacobs (151) and Liu (152). To be eligible for
the whole grain health claim foods have to contain more than 51% of whole grain (all proportions
of kernel) according to the US FDA (153).
  There is increasing data available on the health benefits of whole grain intake (149). Whole grain
food consumption has been linked to reduced risk of T2DM, CVD, some cancers and assistance in
weight maintenance (98,154-163). Moreover, effects of whole grain foods on obesity (164),
hypertension (165,166) and diseases of the digestive system (167,168) have been reported.
2.3.2 Whole grain and T2DM
There are many explanations on how whole grain foods might prevent or delay the onset of T2DM.
Some studies have been conducted to evaluate the relationship between whole grain foods and
glucose metabolism. Pereira et al. (169) tested the hypothesis that whole grain food consumption
improves insulin sensitivity in overweight and obese adults. Fasting insulin was 10% lower during
consumption  of  the  whole  grain  diet.  The  authors  concluded  that  insulin  sensitivity  might  be  an
important mechanism whereby whole grain foods reduce the risk of T2DM and CVD. Whole grain
foods containing intact or poorly grounded kernels or viscous fiber, result in lower postprandial
glucose and insulin responses than the refined grain products (163). Moreover, whole grains foods
have relatively low energy density, which is mainly due to cereal fiber. This promotes satiation and
satiety leading to decreased overall energy intake (170). Finally, the high content of antioxidants in
the whole grain foods may have potential effects on decreasing oxidative stress, a manifestation of
T2DM (171).
2.3.2.1 Epidemiological evidence
Several epidemiological studies have shown an inverse relationship between whole grain
consumption and the risk of developing T2DM (98,154-160). Table 5 describes these studies in
detail. High intake of whole grains is associated with decreases in insulin resistance (164,172,173).
There is also evidence that whole grain intake may be a protective factor against MetS (165,174).
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Whole grain intake has been shown to be negatively associated with MetS in healthy older adults
(175). In the cross-sectional study of 827 Iranian subjects, Esmaillzadeh and colleagues showed that
whole grain intake has an inverse association with the metabolic syndrome (165).  In addition to
MetS, some cross-sectional studies have shown that whole grain intake has an inverse relationship
with insulin resistance and inflammation (161), insulin and total cholesterol (176), BMI
(162,177,178) and glucose concentration (175,178).
In addition to whole grain intake, more specifically cereal fiber intake has also been associated
with a reduced risk of T2DM in large prospective cohort studies. The first large prospective cohort
studies were published already 1997 by Salmeron and colleagues (159). In the Health Professionals
Follow-up Study, the relative risk for diabetes in a cohort of more than 43,000 men was 0.70 for
men in the highest quintile compared to the lowest quintile of cereal fiber intake. Men who
consumed 10.2 g/day of fiber had 30% reduction in the risk when compared to men consuming
2.5g/d. Salmeron and co-workers published another study in the same year (160), which consisted
of 65,000 women. This study showed the relative risk of 0.72 when comparing the highest quintile
to the lowest. Meyer et al. (155) showed that women in the highest quintile of dietary fiber intake
had a 22% lower risk of developing diabetes than did women in the lowest quintile. In the Finnish
Mobile Health Clinic Examination Survey, the relative risk between the extreme quartiles of cereal
fiber intake was 0.39 (156). Stevens et al. (179) reported the association of cereal fiber with T2DM
among the white and African-American population. The hazard ratio for the fifth compared with the
first quintile of cereal fiber intake was 0.75 in whites and 0.86 in African-Americans. Schulze et al.
(98) reported recently the effects of cereal fiber on T2DM in more than 90,000 younger and middle-
aged women.
T
ab
le
 5
. E
pi
de
m
io
lo
gi
ca
l s
tu
di
es
 e
xa
m
in
in
g 
th
e 
as
so
ci
at
io
n 
be
tw
ee
n 
w
ho
le
 g
ra
in
 c
on
su
m
pt
io
n 
an
d 
T
2D
M
.
St
ud
y
P
op
ul
at
io
n
n
F
ol
lo
w
up
 t
im
e 
(y
)
R
R
T
2D
M
A
ss
es
sm
en
t
W
ho
le
 G
ra
in
A
ss
es
sm
en
t
Y
ea
r
R
ef
er
en
ce
Io
w
a 
W
om
en
´s
H
ea
lth
 S
tu
dy
35
,9
88
6
0.
79
Se
lf
-r
ep
or
te
d
of
 P
hy
si
ci
an
s 
D
ia
gn
os
is
FF
Q
:
>
25
%
 w
ho
le
 g
ra
in
s
20
00
(1
55
)
H
ea
lth
 P
ro
fe
ss
io
na
ls
Fo
ll
ow
-u
p 
St
ud
y
42
,8
98
10
.3
0.
70
C
on
fi
rm
ed
se
lf
 r
ep
or
t
of
 p
hy
si
ci
an
s 
re
po
rt
FF
Q
:
>
25
%
 w
ho
le
 g
ra
in
s
20
02
(1
54
)
T
he
 F
in
ni
sh
 M
ob
il
e 
C
lin
ic
H
ea
lth
E
xa
m
in
at
io
n
Su
rv
ey
4,
31
6
10
0.
65
*
N
at
io
na
l
R
eg
is
te
r
D
H
:
>
25
%
 w
ho
le
 g
ra
in
s
20
03
(1
56
)
N
ur
se
´s
 H
ea
lth
 S
tu
dy
 II
(w
om
en
)
88
,4
10
12
0.
83
C
on
fi
rm
ed
se
lf
 r
ep
or
t
of
 p
hy
si
ci
an
s 
re
po
rt
FF
Q
20
04
(9
8)
B
la
ck
 W
om
en
´s
H
ea
lth
 S
tu
dy
41
,1
86
8
0.
69
*
Se
lf
-r
ep
or
te
d
of
 P
hy
si
ci
an
s 
D
ia
gn
os
is
FF
Q
:
da
rk
 b
re
ad
, h
ig
h 
fi
be
r,
 b
ra
n 
or
gr
an
ol
a 
ce
re
al
20
06
(1
57
)
N
ur
se
´s
 H
ea
lth
 S
tu
dy
 I
(w
om
en
)
73
,3
27
18
0.
70
C
on
fi
rm
ed
se
lf
 r
ep
or
t
of
 p
hy
si
ci
an
s 
re
po
rt
FF
Q
:
gr
am
s 
of
 w
ho
le
 g
ra
in
s 
fr
om
 a
ll
so
ur
ce
s
20
07
(1
58
)
R
R
= 
R
is
k 
ra
tio
 in
 th
e 
hi
gh
es
t q
ui
nt
ile
 o
r 
qu
ar
til
e*
 o
f w
ho
le
 g
ra
in
 in
ta
ke
 c
om
pa
re
d 
to
 th
e 
lo
w
es
t q
ui
nt
ile
 o
r 
qu
ar
til
e.
FF
Q
= 
Fo
od
 fr
eq
ue
nc
y
qu
es
tio
nn
ai
re
, D
H
= 
di
et
ar
y 
hi
st
or
y 
qu
es
tio
nn
ai
re
20
21
2.3.2.2 Clinical evidence
Several clinical trials have been conducted to evaluate the relationship between whole grain
consumption and insulin action and glucose metabolism. Table 6 summarizes these clinical studies.
Taken together, these studies show that consumption of whole grain products in crossover studies
generally lowers both insulin and glucose responses. However, after consumption of high fiber rye
bread for 8 weeks there is an increase in acute insulin response in IVGT, suggesting that high-fiber
rye bread may have favorable long-term effects on the maintenance of normal ß-cell secretion or on
the improvement of pancreatic ß-cell dysfunction (180).
2.3.3 Cereals as a source of dietary carbohydrates
Carbohydrates are defined as a group of substances with the chemical formula Cn(H20)n. The
classification of dietary carbohydrates can be made both by chemical and functional properties
(Table 7). Traditionally carbohydrates are classified as simple (sugars, i.e. mono- and disaccharides)
or complex (starches, i.e. polysaccharides) on the basis of the number of sugar molecules in their
structure (181). The nutritional classification divides carbohydrates in two broad categories:
digestible and non-digestible (182). Those which are digested and absorbed in human small
intestine ´providing carbohydrates for metabolism´ are called glycemic carbohydrates. Those
passing to the large intestine and forming a substrate for colonic micro flora are called non-starch
polysaccharides and dietary fiber (183).
Carbohydrates are the most important source of energy in the world. They provide most of the
energy in the human diet varying among cultures, countries and economic status. Carbohydrate-
containing foods are also important sources of proteins, vitamins, minerals and other food
components. The current intake of carbohydrates among Finnish men is 47.7E% and in women
50.2E% (184).
Cereal grains provide more energy worldwide than any other type of crop. It has been estimated
that humans obtain more than 50% of their calories from cereals. In Finland, one third of the daily
food energy intake was derived from cereal and bakery products 2007. Cereal and bakery products
accounted for around half of the carbohydrate intake, and over a half of the fiber intake. In this
survey roughly 15% of the daily energy intake came from bread (184).
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2.3.3.1 Starch
Starch typically comprises up to 70% of the dry weight of cereal grains (191). Starch is made of
two types of glucose polymers: amylose and amylopectin. Amylose is a linear glucose polymer
linked through Į-1,4 linkages, whereas amylopectin is highly branched and larger polysaccharide
containing also Į-1,6 branching points (192). Cereal starches contain approximately 25% amylose
and 75% amylopectin (193).
Starch in food can be further classified as rapidly digestible, slowly digestible and resistant starch
(RS) (194). The ratio of amylose to amylopectin is important when determining the rate of
hydrolysis  of  starch.  A  higher  amylose  to  amylopectin  ratio  slows  down  the in vitro starch
hydrolysis, lowers the postprandial insulin response and attenuates the blood glucose concentration
(195).
Resistant starch (RS) is the proportion of starch indigestible in the small intestine of healthy
persons. (196). RS acts as dietary fiber in many ways. It is not hydrolyzed or absorbed in small
intestine, but enters the large intestine where it can be fermented by the local resident bacteria. The
end products of the fermentation of RS are short chain fatty acids (acetic, butyric and propionic
acid) (197). For many foods, a small proportion of the starch present is RS (typically 0–5% of
starch in most cereal products) (198).
2.3.3.2 Non-starch polysaccharides and dietary fiber
Non-starch polysaccharides (NSP) are a group of carbohydrates defined as the polysaccharides that
do not contain the digestible Į-1,4 linked glucose. The NSP present in plant cell walls have a
structural  function  in  defining  the  integrity  of  plant  cells  and  tissues.  There  are  various  NSPs
available  that  differ  in  their  composition  and  glycoside  linkages.  The  main  classes  of  NSP  are
cellulose, hemicelluloses, pectins, and hydrocolloids (198). In cereals, the major NSP are
arabinoxylan, ȕ-glucan and cellulose (198).
The definition of dietary fiber has been under discussion over the years. In 1953, Hipsley first
applied the term ‘dietary fiber’ as a shorthand term for the non-digestible constituents that make up
the plant cell wall in an attempt to distinguish some property or constituent of the food above and
beyond what was then being measured by the crude fiber methods (199). The currently used
definition was published by European Food Safety Authority in 2008. It defines fiber as
carbohydrate polymers with three or more monomeric units, which are neither digested nor
absorbed in the human small intestine and belong to the following categories:
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1. Edible carbohydrate polymers naturally occurring in the food as consumed
2. Edible carbohydrate polymers that have been obtained from food raw material by physical,
enzymatic or chemical means and which have a beneficial physiological effect demonstrated
by generally accepted scientific evidence;
3. Edible synthetic carbohydrate polymers that have a beneficial physiological effect
demonstrated by generally accepted scientific evidence.
The main types of dietary fiber are: NSPs, resistant starch, resistant oligosaccharides; fructo-
oligosaccharides (FOS), galacto-oligosaccharides (GOS), other resistant oligosaccharides and lignin
naturally associated with the dietary fiber polysaccharides (200).
2.3.4 Whole grain phytochemicals
Whole grains are rich in compounds with known health effects. In addition to dietary fiber, whole
grains contain many other compounds that may have protective effects against chronic diseases
(163). Phenolic compounds included derivatives of benzoic and cinnamic acids, anthocyanidins,
quinines, flavonols, chalcones, flavones and amino phenolic compounds (201,202). The
phytochemicals in whole grains can be classified as phenolics, carotenoids, vitamin E compounds,
lignans, ȕ-glucan and inulin. Some of the common phenolic acids found in whole grains are ferulic,
vanillic, caffeic, syringic and p-coumaric  acid.  In  rye,  phenolic  acids  are  the  major  phenolic
compound and ferulic acid being the most abundant (203,204). Most studies relate the potential
health benefits of phenolic acids to their antioxidant activity (205).
   Lignans are an important phytochemical in whole grains. Lignans are classified as phyto-
estrogens along with isoflavonoids and coumestans. Their role in human health has been
extensively discussed (206). Main lignans in rye are syringaresinol, pinoresinol, lariciresinol,
secoisolaricresinol, matairesinol and medioresinol (207). Also lignans have strong antioxidant
properties that account for their health benefits (207,208).  Lignans may prevent diabetes, heart
disease and some hormone-related cancers. Lower cancer rates have been associated with high
intakes of lignans (209). Alcylresorcinols (ARs) are phenolic lipids with a large structural diversity
and  they  are  present  in  the  rye  grain  (210).  ARs  is  one  of  the  major  groups  in  rye,  however  the
knowledge of the biological effects of ARs is very limited (211).
Mechanistic studies have been conducted using “one dietary ingredient” approach which has been
isolated and fed either animal or human subjects. However, apart from the single compounds there
is little known about the physiological effects of a diet high in whole grain. Generally, the
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protective effect seems to be greater for whole grain consumption than for any individual
compound.  Polyphenols have been suggested to play a role in many degenerative diseases mainly
due to their anti-oxidative, anti-inflammatory and anti-carcinogenic activities (212). Recent
intervention studies have shown that biomarkers of CVD risk are affected by polyphenol rich foods,
but the findings are not conclusive (213,214). The bioavailability of the phytochemicals in the
human tissues such as in AT has not been studied. However, this should be the first step for
studying the exact molecular mechanisms of dietary phytochemicals. The bioavailability may be
studied with animal models to study which metabolites and in what concentrations they are found in
different tissues. The effect of phytochemicals on gene expression in human tissue is also unclear.
New approaches to study their complex metabolic effects in different biological levels should be
developed. A systems biology approach creates new opportunities to study these mechanisms.
2.3.5 Effect of carbohydrate foods on postprandial glucose and insulin
responses
The glycemic index (GI) concept was originally introduced as a means of classifying different
sources of carbohydrate (CHO) and CHO-rich foods in the diet according to their effect on
postprandial glycemia (215). The GI ranks foods according to their effects on postprandial glucose
response. The FAO/WHO Expert Consultation on Carbohydrates in Human Nutrition defined GI as
the incremental area under the blood glucose response curve during 1,5-3 h  after a 50 g
carbohydrate portion of a test food, expressed as a percentage of the response to the same amount of
the standard food taken by the same subject (FAO). The standard food is usually either white bread
or glucose.  A related term, the glycemic load (GL) introduced in 1997 is the average GI multiplied
by the amount of carbohydrates in grams divided by 100 (159,160). GL takes also into account the
differences in the quantity of the food. The GI concept has been intensively argued due to several
reasons. For example, there is controversy whether the GI of single food components can predict
the glucose response of the whole mixed meal (216,217). Moreover, there is much variation among
individuals and from day-to-day within individuals (218).
Different foods containing same amounts of available carbohydrate may still have substantial
differences in the postprandial rise of glucose and insulin levels (219,220). This awareness led to
starchy foodstuffs being ranked according to their postprandial glycemic and insulinemic indices
(221). In general, foods with a low degree of starch gelatinization or dense structure, such as pasta
and those with a high level of viscous soluble fiber, such as those based on whole grain barley have
slower rates of digestion. Foods with higher amylose: amylopectin ratio such as legumes and
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parboiled rice tend to have lower GI values. The amount, type and rate of digestion of dietary
carbohydrate are the primary determinants of postprandial glucose and insulin responses. Large
amounts of protein and fat have, however, been demonstrated to affect postprandial responses.
Protein increases insulin and decreases glucose (222) and fat is generally considered to reduce both
glucose and insulin concentrations due to reduced upper gastrointestinal motility (223). There is
also evidence that some whole meal and refined rye breads induce a lower insulin response than
white wheat bread, even though the glucose responses are similar (180,224).
2.4 Nutrigenomics
The health effects of diets have been traditionally assessed with few physiological end-points.
During the past decade modern nutrition research has shifted its focus towards molecular biology
and different “omics” (225-229). The completion of human genome projects has provided tools to
develop high-throughput technologies that can be applied for nutrition research (230).
 Nutrigenomics faces the challenge of building a strong foundation in basic research. However,
there are still many technological difficulties such as management of data, application of new
bioinformatics algorithms, and there are also limitations in access to human tissue (231). Effects of
nutrition on complex diseases cannot be understood without a profound understanding how
nutrients act at molecular level (225). The food that we eat contains thousands of biologically active
substances, many of which may have the potential to provide health benefits (232). These
substances can affect gene expression either directly or indirectly (228,233). Nutrients may acts as
ligands for transcription factors or be metabolized, altering gene regulation or cell signaling or alter
signal transduction pathways (Figure  4). Nutrients influence gene expression mainly through
transcription factors (225,227,229). Altered signaling by nuclear receptors, may contribute to the
pathogenesis of common metabolic diseases such as obesity, insulin resistance and T2DM (234).
  The whole field of gene–nutrient interactions is called nutritional systems biology, and
encompasses the fields of biotechnology, genomics, molecular medicine and human nutrition
(232,235). Tools of systems biology can be used to combine the transcriptome, proteome,
metabolome and clinical outcome of the dietary changes (225).  Nutrtional systems biology studies
the effect of nutrients on the genome (236), transcriptome, proteome (237) and metabolome (238)
i.e. gene expression and protein and metabolite biosynthesis and degradation. From this perspective,
nutrients are dietary signals that are detected by the cellular sensor systems that influence gene and
protein expression and, subsequently, metabolite production (225). Moreover, nutritional systems
biology aims to extrapolate how such subtle changes in diet can affect human health.
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Figure 4. Schematic presentation of the concept of nutrigenomics.  Modified from Elliot and Ong
2002 (232).
Transcriptomic studies allow, at their best, to study the entire transcriptome simultaneously on a
single chip (239). These genome-wide approaches produce an enormous quantity of data, which can
provide hints about the mechanism underlying the beneficial or adversary effects of a certain
nutrient or diet. This technology can help to identify important genes and pathways that play a role
in the pre-disease state and that might, therefore, act as 'molecular biomarkers' (225,229).
 Nutrigenetics, in turn examines the effects of genotype on the interaction between diet and disease
or on nutrient requirements. Nutrigenetics aims to understand the gene-based differences in
response to dietary components that are the most compatible with the health status of individuals
based on their genetic makeup (5). The significance of single nucleotide polymorphisms (SNPs) has
been accentuated since the completion of the Human Genome Project. Currently, the focus is on the
role of SNPs in chronic diseases. A fruitful strategy in approaching and exploring the field of
nutritional research is to borrow methods that are well established in medical and pharmacological
research (235).
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2.4.1 Microarray studies of human adipose tissue
Several microarray studies of human AT have been completed during recent years (240-246). Most
of them have been concentrated on the differences between obesity and non-obesity. Also the
difference between fat depots, between adipocytes and stromal vascular fraction and between
preadipocytes and mature adipocytes have been studied. Only few of them are clinical trials, and
even fewer have investigated the effect of diet without the aim of weight loss.
 There  is  a  study  comparing  the  gene  expression  of  adipocytes  from  obese  and  non-obese  Pima
Indians (247). The analyses indicated that the inflammation/immune response category was over-
represented, and that most inflammation-related genes were up-regulated in adipocytes of obese
subjects. The authors concluded that mature adipocytes have an active role in obesity-related
inflammation (247). Visceral adipose tissue is known to be more metabolically active than
subcutaneous adipose tissue and seems to play a major role in the development of other metabolic
and cardiovascular risk factors. There are microarray studies that have shown the global differences
between the gene expression profiles of these two tissue depots (240-246). Some of these
investigations also showed gender differences in gene expression for the same fat depot suggesting
hormonal control for these genes (248). Moreover, there is a study showing a difference between
adipocytes and stromal vascular cells from obese and non-obese individuals (249). Poitou and co-
workers (250) have investigated the interplay between subcutaneous adipocytes and the stromal
vascular fraction of adipose tissue. This work provides data suggesting that there is interplay
between hypertrophied adipocytes and macrophages (250). There is also data available from the
gene expression profile of human preadipocytes (251).
 Up to date, most of the dietary interventions using microarray technology have been concentrated
on caloric restriction and weight loss (246,252-255). In the year 2004, the first microarray
intervention study investigated the effect of two VLCD diets (2 days and 28 days) on the gene
expression of WAT (252). Gene expression profiling identified inflammation-related transcripts that
were regulated in obese individuals when on  28-day VLCD, but not on a 2-day VLCD. The authors
concluded that weight loss improves the inflammatory profile of obese subjects through a decrease
of proinflammatory factors and an increase of anti-inflammatory molecules. Moreover, the genes
were expressed mostly in the stromal vascular fraction of adipose tissue, which is shown to contain
numerous macrophages (252).
In 2005, Dahlman et al. (253) investigated the effect of two different energy-restricted diets in
obese women. Women were randomly assigned to a moderate-fat, moderate-carbohydrate diet or a
low-fat, high-carbohydrate hypo-energetic (-600 kcal/d) diet for 10 weeks. Both groups losses
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weight approximately 7.5%. However, there were no differences between the diets in gene
expression profiles. It was concluded that macronutrients have a secondary role in changes in
adipocyte gene expression after energy-restricted diets. Most of the changes in gene expression
were under 25%. (253).
Mutch et al. (246) conducted a rather interesting study in which they asked the question, is it
possible to predict which subjects will lose weight during dietary intervention using only a single
adipose tissue gene expression snapshot. The study group found that the gene expression profiles of
responders (8-12 kgs weight loss) they could always be differentiated from non-responders (<4 kgs
weight loss). The prediction accuracy was at best 81%+/-2%. However, the authors concluded that
this prediction accuracy is insufficient for clinical use. Nevertheless, this was the first time in which
adipose tissue gene expression was used to predict a response to dietary intervention in humans.
Determination of the molecular signature of adipose tissue may be the first step on the way for the
personalized nutrition (246).
Kolehmainen et al. (254) conducted a randomized controlled and individualized weight reduction
intervention with 28 individuals with MetS and 18 controls. The intervention lasted 33 weeks and
the weight reduction was 5%. Down-regulation of gene expression involving gene groups of
extracellular  matrix  and  cell  death  was  seen.  The  changes  in  gene  expression  were  concluded  to
reflect a new stable state at the molecular level in AT (254).
A recent study investigated the adipose tissue gene expression from human obese women
according to energy deficit and the fat and carbohydrate content of the diet (255). Two sets of 47
women  followed  up  10  wk  after  either  a  low-fat  (high  carbohydrate)  or  a  moderate-fat  (low
carbohydrate) hypo energetic diet. Both diets induced similar weight loss and similar changes for
most  of  the  biological  variables  except  for  components  of  the  blood  lipid  profile.  The  authors
concluded that energy restriction had a greater impact on variations in human adipose tissue gene
expression than macronutrient composition. However, the macronutrient-sensitive regulation of a
subset of genes may influence adipose tissue function and metabolic response (255).
In addition to the FUNGENUT study, there is only one clinical intervention investigating the
effect of diet without weight loss on AT gene expression (256). In the study by Vijnk et al. the aim
was  to  investigate  the  effect  of  8  week  SFA  and   MUFA-rich  diet  on  insulin  sensitivity,  serum
lipids, and gene expression profiles of adipose tissue in subjects at risk for the MetS. The 20
individuals in this study were non-diabetic, moderately overweight and did not gain or loss weight
significantly during the intervention period. The main result showed that the SFA diet resulted in
increased expression of genes involved in inflammation processes, without changes in morphology
or  insulin  sensitivity.  On  the  other  hand,  the  MUFA  diet  led  to  a  more  anti-inflammatory  gene
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expression profile. The authors concluded that gene expression of AT appears to be affected by diet
before adipose tissue morphology or insulin sensitivity are changed and might, therefore, be one of
the first hallmarks in the development of MetS (256).
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3 AIM OF THE STUDY
This study was undertaken to detect genetic and metabolic changes induced by two cereal-based
diets by applying modern nutrigenomics and molecular biological approaches.
The specific aims of this work are to:
x Study the effect of two different cereal-based diets on gene expression profile of abdominal
SAT in individuals with MetS (Studies I and II).
x Study the effect of the diets on the inflammation markers in persons with MetS (Study I).
x Search novel pathways and genes responding differently to the diets (Study II).
x Examine  the  association  of  SNPs  of IGFBP5 with biomarkers of MetS and T2DM in the
Finnish population (Study III).
x Study the role of IGFBP5 in adipocyte biology in vitro (Study IV).
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4 SUBJECTS AND METHODS
4.1 Study populations and study designs
Table 8 summarizes the study populations and main measurements used in this thesis.
Table 8. Study populations.
Study Publications Gene expression
Genetic
association
Biochemistry
FUNGENUT I-III x x
GENOBIN III x x
DPS III x x
METSIM III x x
Postprandial I x
4.1.1 The Functional Genomics and Nutrition Study (FUNGENUT)
FUNGENUT Study consisted originally of 53 individuals. The FUNGENUT population is a
subpopulation of a previously reported dietary intervention study (257). Inclusion criteria were age
of  40-70 years, body mass index (BMI) 26-40 kg/m2, and three or more of the following five
criteria (National Cholesterol Education Program definition for the metabolic syndrome) (17). IFG
(6.1 – 6.9 mmol/l), waist circumference >102 cm (men) or >88 cm (women), triglycerides >1.7
mmol/l, HDL-cholesterol <1.0 mmol/l (men) or <1.2 mmol/l (women), blood pressure >130/85
mmHg or antihypertensive medication). Persons were excluded if they had overt diabetes or were
taking cholesterol-lowering, corticosteroid, analgesic, or anticoagulant medication. Altogether 47
individuals finished the study.
4.1.1.1 Study design
The study was parallel randomized intervention with a 4-wk baseline period and 12-wk test period
(Figure  5).  At  the  end  of  the  baseline period, the subjects were randomized according to gender,
median age (57 y) and median two-hour plasma glucose (7.35 mmol/l) to either a rye-pasta diet or
to an oat-wheat-potato diet. Subjects replaced their normal breads and baked products with the test
breads during the intervention. The main difference between the studies breads were the
postprandial insulin responses: Oat-wheat bread produced higher postprandial insulin response than
rye bread, whereas the postprandial glucose response were similar. Microarray analysis was
35
performed from the mRNA of subcutaneous adipose tissue (SAT) taken from ten individuals in
each group before and after the diet intervention.
Figure 5. Study design of the FUNGENUT study
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4.1.1.2 Study diet
The effect of  rye bread, shown previously to lower postprandial insulin responses (Study I), were
compared with that of oat and wheat breads, known to have high postprandial insulin responses.
About 50% of the daily bread consumption in the oat-wheat-potato (OWP) group included oat
bread, and similarly, 50% of bread consumption in the rye-pasta (RP) group included endosperm
rye bread. The fiber content of these breads was almost equal (5.4 g fiber/100 g for the oat bread
and 5.7 g fiber/100 g for the endosperm rye bread). The subjects also received other cereal products
during their diet. Otherwise, the diet remained unchanged. Another goal of the dietary counseling
was that the subject’s weight should not change >5% from their baseline weight.
Postprandial challenge
The two test meals to be used in the FUNGENUT study, were done in 19 individuals, a
subpopulation of the FUNGENUT study, for postprandial insulin response. The test meals consisted
of either oat and wheat breads or rye breads.  The meals were served to 19 individuals, in random
order on two separate study visits. Both test meals contained 50 g of carbohydrate available from
the test breads, 40 g of cucumber, and 3 dl of a non-caloric orange drink (sweetened with
sweetening agent).
The oat and wheat bread (OW) portion contain four wheat breads which were commercially
available in Finland (a graham toast, wheat-bran bread, a white wheat bread and a graham
crispbread) and whole meal oat bread (60% oats) which was produced by VTT Biotekniikka,
Espoo. The whole meal oat bread constituted half of the available carbohydrates (25 g) in the test
portion. The remaining half was composed of equal portions (6.25 g) of the other four breads.
The rye bread portion contain four rye breads which were commercially available in Finland (two
whole meal rye breads, a whole-kernel rye bread and a dried product, namely crisp bread) and an
endosperm rye bread which was produced by VTT Biotekniikka, Espoo. The endosperm rye bread
constituted half of the available carbohydrates (25 g) in the test bread portion. The remaining half
was composed of equal portions of the other four breads. The nutrient composition of the test
breads produced by VVT is represented in Table 9.
Blood samples were drawn through the catheter at fasting state and at 15, 30, 45, 60, 90 120, 150
and 180 min after the beginning of eating. Plasma glucose, serum insulin and FFAs were analyzed
at every time point. Samples for plasma catecholamine (adrenalin, noradrenalin) measurements
were taken at time points 0, 60, 120 and 180 min.
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Table 9. Nutrient composition of the test bread portions.
OW bread Rye bread
Portion size (g) 125 113
Available carbohydrate1 (g) 50 50
Total dietary fiber (g) 6.2 9.7
Soluble dietary fiber (g) 2.2 3.1
Protein (g) 16.3 7.7
Fat (g) 5.1 1.5
Ash (g) 2.2 1.7
Moisture (g) 45.1 41.1
Energy content (kJ) 1314 1031
1available starch + sugars (glucose, fructose, sucrose and maltose)
4.1.2 The Finnish Diabetes Prevention Study (DPS)
DPS is a randomized multicenter study with five participating centers in Finland, located in Kuopio,
Tampere, Helsinki, Oulu and Turku (91). The main target of the study was to assess the effect of an
individually designed diet and exercise program in prevention of T2DM in Finnish individuals with
impaired glucose tolerance.  The study demonstrated that the risk of T2DM was reduced by 58% in
the intensive exercise and diet group when compared to a control group. The specific study design,
methods and outcomes have been reported earlier in detail (91,258). Briefly, the main inclusion
criteria were BMI over 25 kg/m2, age between 40-64 and IGT defined according to the WHO 1985
criteria, i.e. a plasma glucose concentration 7.8-11.0 mmol/L two hours after 75g glucose
administration with non-diabetic fasting plasma glucose concentration (<7.8 mmol/L). A total of
522 subjects were randomly assigned to two treatment groups: the intensive diet and exercise group
or to a control group. The DNA was available from 507 individuals (166 men and 341 women).
4.1.3 The Genetics of Obesity and Insulin resistance Study (GENOBIN)
The GENOBIN study included 75 overweight or obese (BMI 28–40 kg m-2) individuals aged 40–70
years. The individuals had IFG (fasting plasma glucose concentration 5.6–7.0 mmol/L) or IGT (2-h
plasma glucose concentration 7.8–11.0 mmol/L) and other features of metabolic syndrome
according to the NCEP: ATPIII criteria (17,259). Individuals were randomized in to one of the
following groups: a weight reduction group, aerobic exercise group, resistance exercise group or a
control group. Individuals were matched for age, gender, BMI and status of glucose metabolism. In
addition, 11 normal-weight individuals were recruited. The weight reduction group underwent a 12-
wk individualized weight reduction period followed by a weight maintenance period for average
duration of 21 weeks. The individuals were advised to maintain their habitual level of physical
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exercise. Individuals in exercise groups were assigned to personalized and progressive training
programs which lasted 33 weeks (254). In this thesis only the baseline data is used from the
GENOBIN study population.
4.1.4 The Metabolic Syndrome in Men Study (METSIM)
METSIM study consists of a random population-based sample of Finnish 50–70-year-old men
living in the city of Kuopio in Eastern Finland (260). The diagnosis of T2DM was carried out
according to the WHO 1999 criteria. In this thesis, associations found between IGFBP5 gene
variation and adiponectin blood concentrations in the DPS were also replicated in the METSIM
cohort (n=2604).
4.1.5 Approval of Ethics Committee
All of the individuals gave a written informed consent before participating in the study.  The
Committee  of  the  District  Hospital  Region  of  Northern  Savo  and  Kuopio  University  Hospital
approved the FUNGENUT, GENOBIN and METSIM studies. The DPS study protocol was
approved by the Ethics committee of the National Public Health Institute in Helsinki. All of the
interventions were performed in accordance of Helsinki Declaration.
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4.2 Methods
4.2.1 Anthropometric measurements
Height  and  weight  were  measured  in  light  clothing,  and  the  BMI  was  calculated  (BMI=  weight
(kg)/ height (m) 2). Waist circumference was measured halfway between the lowest rib and the iliac
crest. Body composition was assessed by bioelectrical impedance (BIA 101S with BODYGRAM
software; Akern Srl Bioresearch, Florence, Italy). Blood pressure was measured using a standard
sphygmomanometer twice in the right arm after 10 min rest with the subject in sitting position. The
mean systolic and diastolic blood pressure was calculated from the two measurements obtained.
4.2.2 Biochemical measurements
4.2.2.1 Glucose and insulin measurements
Oral and intravenous glucose tolerance tests were performed. In the FUNGENUT study, the fasting
samples were drawn before individuals drank 75 g of glucose solution 300 mL within 3 min. Blood
samples were drawn 15, 30, 45, 60, 90 and 120 min after the glucose ingestion for the measurement
of plasma glucose and serum insulin concentrations. In the GENOBIN study, a frequently sampled
intravenous glucose tolerance test (FSIGT) was performed according to the Minimal Model
method.  In  the  DPS  study,  a  2-h  OGTT  was  performed  after  12-hour  overnight  fasting  with
measurements of glucose and insulin at 0 and 120 min.
In the FUNGENUT study, the plasma glucose was analyzed by using the glucose dehydrogenase
photometric method (Merck Diagnostica, Darmstadt, Germany) and KonePro Clinical Chemistry
Analyzer (Thermo Clinical Labsystems; Konelab, Vantaa, Finland). In GENOBIN and in METSIM
studies plasma glucose concentration was analyzed by the hexokinase method (Thermo Clinical
Labsystems; Konelab, Vantaa, Finland). Serum insulin concentrations were analyzed in
FUNGENUT and GENOBIN studies using the chemiluminescence sandwich method (ACS 180
Plus Automated Chemiluminescence System; Bayer Diagnostics, Tarrytown, NY).  In the DPS
study, a linear-regression equation was calculated for each center, with the use of the plasma
glucose measurement determined at the National Public Health Institute laboratory in Helsinki as
the standard (91). The serum insulin concentration was measured in a central laboratory by a
radioimmunoassay method (Pharmacia, Uppsala, Sweden). Serum insulin was determined with an
immunoluminometric method (Avidia Centaur IRI) on Avidia Centaur Immunoassay System (both
from Siemens Medical Solution Diagnostics, Tarrytown, NY, USA).
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The insulinogenic index was determined in the FUNGENUT study by the increment in insulin
during the first 30 min after oral glucose ingestion divided by the corresponding increment in
glucose. The quantitative insulin sensitivity check index (QUICKI) was calculated as 1/(ln insulin
concentration + ln glucose concentration) (261). Based on OGTT the insulin sensitivity index (SI),
glucose effectiveness (SG) or acute phase insulin response to glucose (AIR) were calculated by the
MINMOD Millennium software in the GENOBIN study (262).
4.2.2.2 Lipid measurements
In the FUNGENUT study the concentrations of total and lipoprotein cholesterol and total
triglycerides were analyzed with a Kone Pro Clinical Chemistry Analyzer (Thermo Clinical
Labsystems, Konelab, Espoo, Finland) using enzymatic methods (Roche Diagnostics, Mannheim,
Germany). Plasma free fatty acids (FFAs) were determined by an enzymatic method from Wako
Chemicals GmbH (Neuss, Germany).
4.2.2.3 Plasma cytokine measurements
Plasma cytokines, i.e. tumor necrosis factor- Į (TNF-Į), interleukin-1ȕ (IL-1ȕ), interleukin 6 (IL-6)
and interleukin-10 (IL-10) were measured using high-sensitivity ELISA kits (R&D Systems,
Minneapolis, MN).
4.2.2.4 Adrenaline and noradrenaline measurements
Briefly, plasma samples were collected into tubes in ice containing EGTA (Ethylene glycol-bis(2-
aminoethylether)-N,N,N',N'-tetraacetic acid) and reduced glutathione as a preservative. Samples
were centrifuged and plasma stored frozen at -70 °C until analyzed. For the analyses Chromsystems
#5000 reagent kit for HPLC analysis of catecholamine in plasma (Chromsystems Instruments and
Chemicals GmbH, Munich, Germany) was used according to manufacturer's instructions. Intra-
assay variation for noradrenaline was 4.1-6.7%, and for adrenaline 3.5-8.5%. Inter-assay variation
for noradrenaline was 7.1-7.2%, and for adrenaline 7.6-10.1%.
4.2.2.5 Serum adiponectin measurements
In DPS study, serum adiponectin measurements were available from 243 individuals at baseline, (M
85/ F158) (B-Bridge International Inc, CA, USA). In METSIM study adiponectin was determined
with Human Adiponectin ELISA-kit (B-Bridge International Inc. CA, USA).
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4.2.3 Adipose tissue biopsy, adipocyte isolation and cell size determination
Subcutaneous adipose tissue biopsies were taken under local anesthesia (Lidocain 10 mg/ml; Orion
Pharma, Espoo, Finland) by needle biopsy from individuals in the FUNGENUT and GENOBIN
studies after 12-hour fasting. The biopsy sample was taken from the superficial abdominal
subcutaneous adipose tissue lateral to the umbilicus. The adipose tissue biopsies were immediately
washed with PBS (Invitrogen, Carlsbad, CA, USA). A small piece was taken for cell size
determination  and  rest  of  the  sample  was  used  for  RNA  extraction.  These  samples  for  RNA
extraction  were  immediately  stored  in  RNAlater  (Ambion,  Austin,  TX,  USA)  at  4°C.  After  24  h,
RNAlater was removed and samples were stored at -80°C until used for RNA extraction.
The median cell diameter was estimated by direct microscopy of isolated adipocytes (263,264).
Briefly, adipocytes were isolated in the presence of collagenase as described in Study I.  After  60
minutes incubation cells were filtered through nylon cloth and washed three times with the same
buffer without collagenase. After 60 min cells were filtered through nylon cloth and washed three
times with the same buffer without collagenase. Direct microscopic determination of the adipocyte
diameter was performed by placing an aliquot of cell suspension in a Bürker chamber and
examining  with  a  microscope.   The  diameters  of  100  -  200  cells  were  estimated.  The  median  of
diameters was used for the calculation of fat cell volume.
4.2.4 RNA isolation from adipose tissue, primary adipocytes and SGBS cells
Total RNA from adipose tissue (Study I-III) and cultured adipocytes (Study IV) was extracted using
TRIzol (Invitrogen, Carlsbad, CA, USA) followed by purification with RNeasy Mini-Kit columns
(Qiagen, Valencia, CA, USA) according to the manufacturer´s instructions. Adipose tissue samples
were lyzed in TRIZOL using a tissue homogenizer. SGBS-cells were lyzed using the QIASchredder
protocol (Qiagen, Valencia, CA, USA). RNA concentration and the A260/A280 ratio was determined
using a NanoDrop-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The
integrity of the RNA was assessed using agarose gel electrophoresis.
4.2.5 Oligonucleotide microarray
Synthesis  of  biotin-labeled  cRNA,  hybridization  to  DNA microarrays  (Affymetrix  HG-U133 Plus
2.0 GeneChip) and detection of hybridized cRNA were performed according manufacturer´s
instructions  (Affymetrix  Inc.,  Santa  Clara,  CA,  USA).  Briefly,  total  RNA  was  used  to  generate
double-stranded cDNA by reverse transcription using the One-Cycle cDNA Synthesis Kit
(Affymetrix Inc.). Labeled cRNA was prepared by using double-stranded cDNA as a template by in
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vitro transcription using the IVT Kit (Affymetrix Inc.). Biotinylated cRNA was fragmented and
added to the hybridization cocktail. The cocktail was used for hybridization of HG-U133 Plus 2.0
array (Affymetrix Inc.) in a hybridization oven 60 rpm at 45°C for 16 h, followed by washings
using  the  GeneChip  Fluidics  Station  400  (Affymetrix  Inc.).  The  arrays  were  stained  with
streptavidin-phycoerythrin (Molecular Probes, Eugene, OR, USA), incubated with biotinylated anti-
streptavidin IgG (Vector Laboratories, Burlington, Canada) and stained again with streptavidin-
phycoerythrin.
4.2.6 Real-time quantitative PCR
Total RNA was reverse transcribed to generate cDNA using the High Capacity cDNA Archive Kit
according manufacturer's protocol (Applied Biosystems, Foster City, CA, USA).  Quantitative real-
time PCR analyses were performed with TaqMan® chemistry using commercial ready made assays
according to the manufacturer´s protocol (Applied Biosystems, Foster City, CA, USA). The assays
used in the study are listed in the Table 10. All the samples were analyzed in triplicates using ABI
Prism 7500 Real-Time PCR system. Both absolute quantification with a modification of an
additional standard curve (Study I-III) and ǻǻCt method were used (Study IV) using methods
described in the ABI Prism User Bulletin # 2. The endogenous control was chosen by using the
Human Endogenous Control Kit (Applied Biosystems). Of the 11 possible candidates, cyclophilin
A1  (PPIA) was chosen as the best candidate when cDNA pool constructed from isolated human
adipose tissue RNA was used as a template.
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Table 10. ABI assays used in the Studies I-IV.
Gene symbol Description ABI assay ID
ADIPOQ adiponectin Hs006505917_m1
FTO fat mass and obesity associated Hs01057145_m1
IGFBP1 insulin-like growth factor binding protein-1 Hs01065514_m1
IGFBP2 insulin-like growth factor binding protein-2 Hs01040719_m1
IGFBP3 insulin-like growth factor binding protein-3 Hs00426299_m1
IGFBP4 insulin-like growth factor binding protein-4 Hs01057900_m1
IGFBP5 insulin-like growth factor binding protein-5 Hs01052296_m1
IGFBP6 insulin-like growth factor binding protein-6 Hs00942697_m1
IGFBP7 insulin-like growth factor binding protein-7 Hs00266026_m1
IGF-I insulin-like growth factor -1 Hs01547657_m1
IL10 interleukin 10 Hs00174086_m1
IL10RĮ interleukin 10 receptor Į Hs00609811_m1
IL-1ȕ interleukin 1ȕ Hs00174097_m1
Leptin leptin Hs00174877_m1
NAMPT nicotinamide phosphoribosyltransferase Hs00237184_m1
PAI-1 plasminogen activator inhibitor-1 Hs00167155_m1
PPAR-Ȗ peroxisome proliferator-activated receptor- Ȗ Hs0107722_m1
PPIA cyclophilin A 1 Hs99999904_m1
SLC40A1 solute carrier family 40 Hs00976236_m1
SPP-1 secreted phosphoprotein 1 Hs00959010_m1
TCF7L2 transcription factor 7-like 2 (T-cell specific, HMG-box) Hs01009038_m1
TNF-Į tumor necrosis factor Į Hs00174128_m1
4.2.7 Data extraction and statistical analyses of microarrays
The gene chips were scanned with the HP GeneArray Scanner 3000 (Affymetrix Inc). Data were
extracted using Affymetrix GeneChip Operating Software 5.0 (GCOS). Gene expression profiles
were compared using dChip software (www.dchip.org). Invariant set normalization (265) was used
to normalize arrays at the probe level. Model-based expression index (MBEI) signals were then
calculated according to the PM/MM-model. The data was further filtered so that the genes which
were called “present” in more than 50% of the replicates in at least one of the two time points. In
addition to p-values, the false discovery rate (FDR or q-value) was used to determine the significant
changes in the genes using Significance Analysis of Microarrays (SAM) (266). Pathway analyses
were conducted with Panther Classification System Version 6.0 (www.pantherdb.org) (267) and the
Database for Annotation, Visualization and Integrated Discovery 2.1, DAVID 2.1
(http://david.abcc.ncifcrf.gov/) (268).
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4.2.8 Selection of IGFBP5 polymorphisms
The eight SNPs along the IGFBP5 gene ~23 kb and flanking regions (r 10 kb) were selected for
association studies based on Tagger Software (269) using data from the International Hap Map
Project (270). Haploview software was used for linkage disequilibrium analysis (271). Genotyping
of  the  SNPs  was  performed from 507 DPS subjects  (166  men and  341  women)  whose  DNA was
available. The SNPs were selected using Tagger Software, and they covered 80.8% of alleles in the
studied region (Figure 6).
Figure 6. The location of selected markers in the IGFBP5 gene (A), and their pairwise linkage
disequilibrium values: D´ (upper) and r2 (lower) values) (B). White boxes, UTR; black boxes,
coding region.
4.2.9  TaqMan allelic discrimination assays
The genotyping was performed with TaqMan Allelic Discrimination Assays according
manufacturer´s  instructions  (Applied  Biosystems,  Foster  City,  CA,  USA).  The  PCR amplification
was performed in the ABI GeneAmp 2700 PCR system (Applied Biosystems) under the following
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PCR program: 10 minutes at 95ºC, followed by 40 cycles of denaturation 92ºC for 15 sec and
annealing at 60 ºC for 60 sec.
4.2.10  Immunohistochemical staining
From formalin-fixed, paraffin-embedded human subcutaneous adipose tissue samples, 5 µm tissue
sections were cut and placed on poly-L-lysine-coated glass slides.  The sections were incubated at
58ºC for 30 minutes followed by deparaffination and dehydration in xylene and graded alcohol
treatments. Antigen retrieval was done in a microwave oven for 3x5 minutes in a citrate buffer (10
mM, pH 6.0). Endogenous peroxidase activity was blocked with 3% H2O2, washed with citrate
buffer and incubated with 1% bovine serum albumin (BSA) in phosphate buffer in 37 ºC for 30
minutes to block non-specific binding. The sections were incubated overnight at 4ºC  with
polyclonal anti-IGFBP5 antibody diluted in 1% BSA (dilutions 1:100, 1:300 and 1:500, ab 4255,
Abcam Inc. Cambridge, MA, USA) (272). This was followed by 1 hour incubation with
biotinylated polyclonal antirabbit antibody (dilution 1:20, ab 6791, Abcam Inc. Cambridge, MA,
USA) in 1% BSA. The bound antibodies were visualized with an indirect avidin-biotin-peroxidase
method (ABC Vectastain Elite kit; Vector Laboratories). The sections were incubated for 5 min in
0.05% 3,3´-diaminobenzidine (DAB, Sigma-Aldrich, St. Louis, USA) and 0.03% H2O2 in phosphate
buffer. After washes with distilled water, the sections were counterstained with Mayer´s
hematoxylin for 1 min, washed, dehydrated in graded alcohols, mounted in DPX (Gurr®, BDH
Laboratory Supplies, Poole, UK) and coverslipped. The negative controls were obtained by
omitting the primary antibody. The micrographs were obtained using Microphot FXA microscope
(Nikon Corp., Japan) using 40,100 and 200x objectives and CoolSNAP camera (Photometrics).
4.2.11  Cell culture
Human subcutaneous preadipocytes (PT-5020), growth mediums and supplements were purchased
from Lonza Group Ltd (Switzerland). Cells were grown in Preadipocyte Growth Medium-2
containing 10% fetal bovine serum, 2 mM L-glutamine and penicillin/streptomycin, 100 units/ml
and 100 µg/ml, respectively in the presence of 5% CO2 at 37°C (273). To induce adipogenesis in
vitro the SingleQuots® containing 0.01 mg/ml insulin, 0.1 ȝM dexamethasone and 25 mM IBMX
(Lonza Ltd, Switzerland) was added to PGM-2 according to manufacturer´s instructions. On a day
4-5 the lipid vacuoles appeared and on days 7-10 they increase in size. After day 10 the cells were
fully differentiated.
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The gene expression of seven IGFBPs (1-7), adiponectin, IGF-I and PPAR-Ȗ was studied in
different stages of differentiation. Specifically, mRNA was extracted on days 0 (preadipocyte) 2, 4,
8 and 10 after the initiation of adipogenesis. Moreover, the gene expression was also studied from
mature adipocytes (day 10) treated with TNF-Į (Sigma-Aldrich, St. Louis, USA) (20 ng/mL), IL-1ȕ
(Peprotech, UK) (10 ng/mL), IL-10 (Peprotech, UK) (10 ng/mL), recombinant human IGFBP5
(Prospec, Tany TechnoGene Ltd, Israel) (0.01, 0.1, 1 µg/mL ± insulin) and adiponectin (Prospec,
Tany TechnoGene Ltd, Israel) (10 µg/mL ± insulin) for 24 h. The Simpson-Golabi-Behmel
Syndrome cells (SGBS) originally derived from stromal fraction of subcutaneous adipose tissue of
an infant. The cells were cultured as described previously (274). Briefly, SGBS cells were cultured
at 37ºC and grown in DMEM/F12 Nut mix (1:1, Invitrogen, Carlsbad, CA) medium supplemented
with 33 µmol/L biotin (Sigma-Aldrich), 17 µmol/L pantothenate (Sigma-Aldrich), 1% antibiotics
(penicillin/streptomycin, Invitrogen) and 10% FCS (Invitrogen) until confluent. To induce
adipocyte differentiation, cells were washed several times with phosphate-buffered saline
(Invitrogen) and cultured in serum-free basal medium DMEM/F12, 33 µmol/L biotin, 17 µmol/L
pantothenate, 1% antibiotics, 10 µg/mL transferrin (Sigma-Aldrich), 20 nmol/L insulin (Sigma-
Aldrich), 0.1 µmol/L hydrocortisone (Sigma-Aldrich), 0.2 nmol/L triiodo-L-thyronine (T3)
supplemented with 25 nmol/L dexamethasone (Sigma-Aldrich), 0.5 µmol/L 1-methyl-3-
isobutylxanthine (IBMX, Sigma-Aldrich) and 2 µmol/L rosiglitazone, PPARȖ agonist, BRL 49653
(Cayman Chemical, Ann Arbor, Michigan). After 4 days, the medium was replaced with serum-free
basal medium supplemented 25 nmol/L dexamethasone, 0.5 µmol/L 1-methyl-3-isobutylxanthine.
After 3 days, the medium was replaced with serum-free basal medium and changed twice a week.
Experiments  were  performed  on  day  14  of  postdifferentiation.  Cell  culture  experiments  were
performed in triplicates and repeated twice if not indicated otherwise. In these studies cyclophilin
A1 was always used as an endogenous control gene.
RNA interference
RNA interference technology was used to knock-down IGFBP5 gene expression in the SGBS cells.
SiRNA for Human IGFBP5 (NM_000599), ON-TARGETplus SMARTpool was purchased from
Dharmacon (Dharmacon Inc, Chicago, IL). SiRNA was transfected by using HiPerFect transfection
reagent (Qiagen, Valencia, CA) and Allstars SiRNA (Qiagen, Valencia, CA) was used as a
scramble (negative control) according to manufacturer´s instructions. Briefly, SGBS cells were
induced into adipocytes as described earlier. On day 14 of differentiation, the medium was replaced
with DMEM/F12 Nut mix (1:1) supplemented with 33 µmol/L biotin, 17 µmol/L pantothenate, 10
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µg/mL transferrin, and 20 nmol/L insulin. The cells were transfected with 20 nmol/L SiRNA and
incubated for 48 hours. Knock-down of IGFBP5 was confirmed by RT-PCR.
4.2.12 Statistical methods
Study I
Postprandial insulin, glucose and FFA responses were analyzed with multivariate ANOVA. The
difference between the test portions of individual time points were analyzed only if there was an
overall significance between the groups with ANOVA. Plasma cytokine concentrations from long-
term diet intervention were analyzed with a general linear model for repeated measures corrected
with the baseline variable. Differences in catecholamine concentrations were determined with
Wilcoxon non-parametric paired test (oat wheat bread vs. rye bread).
Study II
Statistical analyses were performed with the SPSS software versions 11.5 and 14.0 for WINDOWS
(SPPS Inc, Chicago, IL, USA). Normal distribution of variables was tested with Kolmogorow-
Smirnov test. Variables with skewed distributions by Shaphiro-Wilks test were normalized with
logarithmic or reciprocal transformation. Information of variables is given as mean ±SD in
untransformed values unless otherwise mentioned. The General Linear Model (GLM) for repeated
measures was used for analyzing the differences between the groups (the interaction of time and
group) during the intervention with the corresponding baseline variable included in the analysis as a
covariate. GLM for univariate analysis was used to assess the difference in the change-values (¨) of
insulinogenic index and QUICKI between the groups with the baseline variable as a covariate. The
paired samples T-test was used to examine the changes in variables within each group.
Study III
Haploview software (271) was used for linkage disequilibrium analysis, and association studies
were performed with SPSS14.0 for Windows (SPSS, Chicago, Ill., USA). The data are presented as
means±SD (tables) or means±SEM (figures), and the combination of p<0.05 and q-value <0.25 was
considered statistically significant. The differences in genotype frequencies among genders and
groups among individuals with different genotypes were tested with Pearson´s Ȥ2-test. The genetic
associations with continuous variables at baseline were analyzed with the general linear model
(GLM) univariate analysis of variance (ANOVA) using appropriate adjustments. Kruskal-Wallis
test  was  applied  to  variables  whose  distribution  could  not  be  normalized.  The  p-values  were
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adjusted for gender, baseline age and BMI. If the genotype*gender- interactions were observed,
stratified analyses according to gender or group were performed to further investigate the genotype
effect. In this case, p-values were adjusted with age and BMI. Correction for multiple hypothesis
testing was performed with false discovery rate (FDR) using Q-value 1.0 software (275) ʌ0 was
estimated with bootstrap method using Ȝ range from 0 to 0.9 by 0.05.
Study IV
The statistical analysis was carried out using GraphPad Prism 4.03 for Windows (GraphPad
Software, San Diego, CA). Data are expressed as means ±SEM unless indicated otherwise. The
analysis of gene expression data during differentiation and different treatments were analyzed with
One-Way ANOVA with use of Dunnets´s Multiple Comparison Test in order to comparing baseline
(day  0)  to  other  time  points.   SiRNA  results  were  analyzed  with  Student´s  T-test  comparing  the
silencing effects to scramble treatment.  A value of P<0.05 was considered statistically significant.
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5 RESULTS
5.1 Postprandial responses to different bread portions
The test meal with oat and wheat bread (OW) produced a higher insulin AUC (p<0.01) and
maximal increase of insulin than rye bread (p<0.001). Interestingly, the glucose AUC, maximal
glucose response or glucose peak time did not differ between the groups (Figure 7).
Figure 7. Mean (±SEM) plasma glucose (a) and serum insulin (b) in responses to rye bread (Ŷ) and
oat and wheat bread (ż) portion in subjects with MS (n=19). a) Multivariate ANOVA (p<0.001) b)
Multivariate ANOVA (p<0.01).
FFAs were elevated significantly (P=0.048) in the later postprandial phase after the oat and wheat
bread compared with the rye bread test meal. Moreover, there was an increase in the postprandial
plasma adrenaline concentration after the oat and wheat bread meal from 60 to 120 min (P<0.05).
There was no difference between the groups in plasma noradrenaline concentrations.
5.1.1 Inflammation markers in response to study diets
Gene expression profiles from SAT were studied for IL-1ȕ, IL-10, TNF-Į and IL-10RĮ and plasma
cytokine concentrations were measured from IL-1ȕ, IL-10, TNFĮ and IL-6.
There was a significant difference between the study groups in IL-10RĮ gene expression (p<0.01).
The OWP diet up-regulated the gene expression of IL-10RĮ by 1.4 fold, whereas the RP diet down-
regulated the expression. TNF-Į was up-regulated by 1.24 fold in response to the oat-wheat-potato
diet (p<0.05).
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There was a significant difference (p<0.05) between the groups in IL-1ȕ plasma concentration,
showing an increasing trend for the OWP diet and an opposite trend for the RP diet after the
interventions. Similar trend with a borderline significance was detected for plasma IL-6
concentration (p=0.055). HsCRP remained unchanged during the interventions.
5.2 Clinical characteristics of FUNGENUT study
The baseline characteristics did not differ between the groups except for systolic blood pressure
(Table 11). Body weight did not change during the interventions. The insulinogenic index showed a
borderline significant difference between the groups. In the RP diet group the insulinogenic index
improved by 21% (p=0.004). There was no significant difference between or within the groups in
the plasma glucose concentrations in an OGTT at the beginning (0 wk) or at the end (12 wk) of the
intervention.
Table 11. Baseline characteristics of the FUNGENUT population (mean ±SD).
RP diet group OWP diet group
N (male/female) 21 (13/8) 26 (15/11)
Age (y) 54.0 ± 6.8 56.0 ± 6.0
BMI (kg/m2) 31.7 ± 0.5 32.2 ± 3.7
Waist circumference (cm) 110  ± 11.4 108 ± 9.0
Systolic blood pressure (mmHg) 136  ± 15.4 145 ± 15.6
Diastolic blood pressure (mmHg) 88  ± 9.6 87 ± 9.0
Fasting plasma glucose (mmol/L) 6.3  ± 0.7 6.3 ± 0.6
Fasting serum insulin (mU/L) 13.7  ± 6.9 13.7 ± 7.0
Fasting serum total cholesterol (mmol/L) 6.1  ± 1.0 5.7 ± 0.8
Fasting serum HDL cholesterol (mmol/L) 1.2  ± 0.3 1.3 ± 0.3
Fasting serum LDL cholesterol (mmol/L) 3.8  ± 0.7 3.6 ± 0.6
Fasting serum triglycerides (mmol/L) 2.1  ± 1.2 1.9 ± 1.3
5.3 FUNGENUT study diets
The reported compliance for consumption of the test breads was very good. The consumption of the
test breads exceeded the amount advised to be consumed during the diet interventions. During the
RP diet intervention carbohydrate, total fiber, soluble and insoluble fiber intake increased. For the
OWP diet the total fiber intake decreased and protein and soluble fiber intake increased.
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5.4 Global gene expression of SAT in response to study diets
Both diets caused significantly different gene expression profiles in SAT as compared to baseline.
After the 12-week RP diet 71 genes were differentially expressed compared to baseline. All of these
genes were down-regulated (p<0.05, FDR=0.18). The genes were closely linked to the insulin and
IGF-pathways, such as insulin-like-growth factor binding protein 5 (IGFBP5) and insulin receptor,
which were down-regulated 0.84 and 0.73, respectively. Moreover, hormone sensitive lipase (LIPE)
was down-regulated 0.85 fold. The pathway analysis grouped seven genes in to a cluster of
apoptosis (p<0.01). One interesting gene responding to RP diet was transcription factor 7-like 2 (T-
cell  specific,  HMG-box) (TCF7L2) due to the fact it is one of the strongest genes associated with
the risk of T2DM (260,276).
On the other hand, the 12-week OWP diet up-regulated 62 genes compared with baseline (p<0.05,
FDR=0.24). These genes formed clusters in biological processes such as protein phosphorylation,
cytokine- and chemokine-mediated immunity, protein modification and in pathways related to
oxidative stress, interleukins and inflammation mediated by cytokines/chemokines.
5.5 Genetic variations of the IGFBP5 gene
12-wk RP diet decreased expression of IGFBP5 mRNA in human subcutaneous adipose tissue with
a simultaneous improvement in the insulinogenic index (Study II). We showed a correlation
between IGFBP5 and adiponectin gene expression in individuals with features of metabolic
syndrome. Based on our previous studies, we hypothesize that IGFBP5 expressed in WAT may be
involved in the link between diet, obesity, insulin resistance and onset of T2DM.
5.5.1 Genotype frequencies, linkage disequilibrium and success rate
The observed genotype frequencies were in Hardy-Weinberg equilibrium. The genotype
frequencies are shown in the Table 12. The SNPs rs9341234 was in linkage disequilibrium with
rs3276; D´and r2 were 0.957 and 0.728, respectively. The success rate for genotyping was 100%.
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Table 12. Genotype frequencies (%) of IGFBP5 in the DPS and METSIM studies.
IGFBP5 SNP Genotype Genotype
frequency in
DPS
Genotype frequency in
METSIM
rs9341234 TT 95.2 -
TC 4.8 -
CC - -
rs3276 GG 94.3 95.3
GA 5.5 4.6
AA 0.2 0.1
rs7420849 GG 24.1 -
GT 49.1 -
TT 26.8 -
rs3755137 TT 81.1 -
TA 17.2 -
AA 1.8 -
rs11575134 GG 73.8 68.2
GA 23.9 29.0
AA 2.4 0.3
rs6727330 TT 50.9 -
TC 38.5 -
CC 10.7 -
rs9967835 GG 83.4 -
GA 16.2 -
AA 0.4 -
rs6738874 AA 50.1 -
AT 40.4 -
TT 9.5 -
5.5.2 Genetic association of IGFBP5 with adiponectin serum concentrations
IGFBP5 SNPs (rs9341234 and rs3276) were associated with circulating adiponectin concentrations
in DPS population (p/q=0.002/0.250, p/q=0.007/0.280, respectively). When the population was
analyzed according to sex, the strongest association was seen in men with rs9341234, rs3276 and
rs11575134 (p/q=0.001/0.001, p/q=0.001/0.001 and p/q=0.001/0.074 respectively), whereas there
was  no  association  in  women  (Figure  8). Haplotype analysis showed that men with haplotype
(rs9341234-T, rs3276-G and rs11575134-A) TGA had lower adiponectin concentrations when
compared with those having the most common haplotype TGG (p=0.017) in DPS. These results are
in accordance with those obtained with corresponding individual SNPs.
 The results were confirmed in the METSIM study (n=2604) for markers rs3276 and rs1157134
(Figure  9). Significant differences in adiponectin concentrations according to genotype of
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rs11575134 among diabetic men (dominant model, p=0.029) and men with impaired fasting glucose
(dominant model, p=0.043) were observed. However, this finding could not be replicated with
rs3276. There was no association between the studied SNPs and the risk of T2DM.
Figure 8. Association of the IGFBP5 markers rs92341234 (a and b), rs3276 (c and d) and
rs11575134 (e) with circulating adiponectin concentrations at baseline in DPS. Data are means ±
SEM.
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Figure 9. Association of IGFBP5 marker rs11575134 with the concentration of plasma adiponectin
in (a) normoglycemic men, (b) men with impaired fasting glucose, (c) men with impaired glucose
tolerance and (d) men with T2DM in METSIM study. Data are means ± SEM.
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5.5.3 Correlations of gene expression between adiponectin and IGFBP5
The gene expression of IGFBP5 and ADIPOQ were correlated with each other in FUNGENUT and
GENOBIN studies at baseline. The gene expression levels were highly correlated in all subjects
(p<0.001. r2=0.368) and in women (p<0.001. r2=0.425).
5.6 Cell culture studies
5.6.1 IGFBP5 expression in SAT and adipocytes
The expression of IGFBP5 in SAT was detected in the oligonucleotide microarray experiment
(Study II). The expression was confirmed with real-time quantitative PCR in the FUNGENUT and
in GENOBIN populations. Moreover, the gene was expressed in commercial primary human
adipocytes and SGBS-cells. Furthermore, the immunohistochemical staining revealed the
localization of IGFBP5 in human adipose tissue (Figure 10).
Figure 10. Light microscopy of human subcutaneous AT. IGFBP5 protein localization is visualized
with immunohistochemical staining. Primary antibody dilution (1:500), A=40x objective; B=200x
objective.
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5.6.2 Gene expression patterns of IGFBPs during adipogenesis
IGFBPs demonstrate three different gene expression patterns in human subcutaneous primary
adipocytes during adipogenesis (Figure 11).The expression of IGFBP5 (Figure 11a) and IGFBP2
(Figure 11b) were up-regulated during the differentiation process (One-way ANOVA, p<0.0001),
whereas IGFBP3 (Figure 11c) and IGFBP6 (Figure 11d) were down-regulated (One-way
ANOVA, p<0.0001). The expression patterns of IGFBP3 and IGFBP6 were opposite such that the
highest expression was seen in preadipocytes and lowest in mature adipocytes. IGFBP4 (Figure
11e) and IGFBP7 (Figure 11f) showed the strongest expression on day 4 after differentiation,
although they were expressed in all stages of the differentiation including the preadipocyte stage
(One-way ANOVA, p<0.0001). IGFBP1 was not expressed in the subcutaneous adipocytes. The
differentiation process was appropriate because known markers such as PPARȖ2, IGF-I and
ADIPOQ were all significantly up-regulated during the differentiation process (See Study IV for
details).
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Figure 11. Gene  expression  of IGFBP gene family during adipogenesis of primary adipocytes.
IGFBP1 was not expressed in the human primary adipocyte. Cyclophilin A1 (PPIA) served as an
endogenous control gene. One-way ANOVA was significant in all cases p<0.0001, Dunnet´s
Multiple Comparison Test, ** p<0.01. Data are represented as means ± SEM. IGFBP, insulin-like
growth factor binding protein.
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5.6.3  Gene expression of adiponectin gene in response to IGFBP5 treatment
Higher concentrations (0.1 µg/mL and 1.0 µg/mL) of IGFBP5 protein introduced into cell media of
primary human adipocytes up-regulated the gene expression of adiponectin by 2.0 and 1.4 fold,
respectively. With lowest dosage (0.01 µg/mL) of IGFBP5 the effect remained non-significant.
However,  the  treatment  of  adipocytes  with  adiponectin  did  not  affect  the  gene  expression  of
IGFBP5 (Study IV).
5.6.4 RNA silencing of IGFBP5
SiRNA of IGFBP5 altered the gene expression of TCF7L2, NAMPT and SPP-1 (Figure 12). The
most interesting finding was a down-regulation of TCF7L2 (-29.7%, P=0.001), a key gene involved
in the Wnt signaling pathway and genetic a risk gene for T2DM. Moreover, also NAMPT (visfatin)
was found to be down-regulated (-19.1%, p=0.031), whereas SPP-1 (osteopontin) was up-regulated
(+52.4%, p=0.048) in response to reduced expression of IGFBP5. Silencing the gene expression of
IGFBP5 did not affect on gene expression of Leptin, PAI-1, FTO or ADIPOQ.
Figure 12. Effect of IGFBP5 siRNA on genes expressed in SGBS adipocytes. SiRNA knock-down
of IGFBP5 by 54% down-regulated gene expression of TCF7L2 and NAMPT, whereas SPP-1 gene
is up-regulated in SGBS-cells. Ŷ= scramble Ƒ=siRNA. Cyclophilin A1 (PPIA) served as an
endogenous control gene. ADIPOQ, adiponectin; NAMPT, nicotinamide phosphoribosyltransferase
or visfatin; SPP-1, secreted phosphoprotein 1 or osteopontin; TCF7L2, transcription factor 7-like 2
(T-cell specific, HMG-box. Students T-test, * p<0.05, ** p<0.01. Data are represented as means ±
SEM.
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6 DISCUSSION
6.1 Methodological considerations
6.1.1 Study populations
All study subjects were carefully selected and clinically well characterized in the studies presented
in this thesis. The subjects were Finnish, and the Finnish population has been considered a model
population for human genetic studies (277). The study subjects used are similar to each other in
many aspects. The subjects in FUNGENUT, GENOBIN and DPS were overweight or obese, in
addition they all had features of MetS. In contrast, the METSIM population was a population-based
sample of men.
In Study I,  19 subjects (9 women and 10 men) with MetS were recruited to participate into two
postprandial challenges before the 12-wk diet intervention (278).
In Studies I and II, forty-seven individuals (23 women and 24 men) with MetS according the
National Cholesterol Education Program (17) were recruited. Study subjects were a sub-population
of a previously reported larger intervention study (n=72) (257). The major limitation of the Study II
considering the results was the fact that we did not have adiponectin measurements.
In Study III, four different study populations were used. The association studies were carried out
using two cohorts, the DPS and METSIM. All subjects in DPS (n= 507, 341 women and 166 men)
had IGT and were overweight. In general, the requirements for genetic association studies have
changed during recent years and genotyping of large sample sizes are becoming a pre-requisite for
studies that are considered in major publication forums (279). The DPS is considered rather small
for genetic association studies. Especially when carrying out statistical analyses in smaller sub-
groups, statistical power is limited. On the other hand, DPS is a homogenous and carefully
characterized sample of Finnish middle aged persons who were at a high risk of developing T2DM.
The study is longitudinal, thus enabling the assessment of long-term gene-environment interactions.
Seventy-five percent of the DPS population had the MetS at the start of the study. A total of 2,604
men from the population-based cross-sectional METSIM (Metabolic Syndrome in Men) study were
included. Subjects aged from 45 to 70 years were randomly selected from the population register of
Kuopio, Eastern Finland (population of 95,000). The population was divided into groups with
normoglycemia, impaired fasting glucose, impaired glucose tolerance and T2DM. METSIM is
considered to be an excellent population to replicate the results obtained from DPS. Drawbacks of
METSIM study are its cross-sectional design (at present), and it was consisted only of men. The
sample size is, however, more appropriate for genetic association studies.
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In Study III, the FUNGENUT (Study I-II) and GENOBIN studies were used in gene expression
analysis.  The  study  subjects  of  GENOBIN  had  either  IGT  or  IFG  and  two  additional  features  of
MetS being very similar study population to FUNGENUT.
6.1.2 Statistical issues
In Studies II and III, both p-values and q-values were used to analyze the microarray and genetic
association data.  Type I errors (false positive results) may occur when many genetic markers with
different phenotypes are investigated. Bonferroni corrections for multiple testing are commonly
used, which is now considered to be too conservative for genetic association studies (280).
Bonferroni corrections may thus introduce type II errors (false negative results). Therefore, to
correct for multiple testing the FDR (false discovery rate) q-value was calculated (275). The FDR
simultaneously corrects for the number of phenotypes and markers that are tested. FDR is also
widely used in microarrays with large data sets (Study II). The presence of an association is based
on a significant p-value. A high q-value means that the association must be interpreted with caution,
because it may represent a false positive finding. A good practice is to replicate the findings in other
studies and populations, as was done in Study III.
6.1.3 Adipose tissue and biopsy technique
In Studies I-IV, human subcutaneous adipose tissue (SAT) was studied. However, visceral adipose
tissue (VAT) is also an active fat depot (240,241). In previous studies, the gene expression profiles
in VAT and SAT have been different from each other (242-244). To elucidate the functional role of
whole white adipose tissue, both depots should ideally be studied simultaneously. Due to limitations
in the biopsy technique and ethical issues, taking VAT biopsies were not considered.
The needle biopsy technique was applied in order to obtain adipose tissue samples. However,
there is recent evidence that this technique might result in an underrepresentation of stromal-
vascular fraction of adipose tissue (281). During this study we did not use surgical biopsies.
6.1.4 Microarray studies
In Study II, the microarray technology was used to screen the effects of the clinical intervention on
gene expression profile of AT and clinical outcome. Interestingly, there were early biomarkers
detected in AT which may lead to worsening insulin resistance and eventually to T2DM.
Study II is the first human study conducted where the effects of a diet intervention without the aim
of  weight  loss  on  the  gene  expression  of  AT.  To  date,  there  is  only  one  clinical  intervention  in
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addition to Study II investigating  the  effect  of  diet  without  weight  loss  on  AT  gene  expression
(256).
Microarray and bioinformatics techniques and technologies are rapidly advancing. At the time the
experiments were done and data analyzed (2006 - 2007), there was no golden standard. However,
the bioinformatics tools used in the present study were also widely used by other authors (252, 282).
Invariant set normalization was used to normalize arrays at the probe level (265). Model-based
expression index signals were then calculated using the PM/MM-difference model. The genes that
were present in >50% of the replicates in 1 of the 2 time points were selected for further analysis.
To compare gene expression profiles between the groups, we used the false discovery rate (FDR) to
determine the significant changes in the genes using Significance Analysis of Microarrays (SAM)
(266).
Based on recent knowledge the bioinformatics approach used in Study II includes some
limitations (283). First, after the multiple hypotheses testing, no individual gene may meet the
threshold of statistical significance even though they may be biologically relevant. Second, this
approach may lead to long list of genes without a unifying biological theme. Third, single-gene
analysis may miss the important enrichment of set of genes in the same pathway. To overcome
these analytical challenges Gene Set Enrichment Analysis (GSEA) was developed to evaluate
microarray data at the level of gene sets (283). Gene Set Enrichment Analysis (GSEA) evaluates
microarray data at the level of gene sets. The gene sets are defined based on prior biological
knowledge, e.g., published information about biochemical pathways or co-expression in previous
experiments.
The data used in the Study II was re-analyzed using gene enrichment set analysis (GSEA) (284).
Clinically relevant pathways were selected from the significantly enriched pathways for further
analysis. Despite of the limitations of the bioinformatics used in this thesis, similar results were also
seen with the GSEA approach. Study II showed that genes related to stress and inflammation was
unregulated in response to OWP diet. Similarly, the GSEA analysis showed an up-regulation of
gene sets related to stress reactions and DNA damage. However, the enrichment and up-regulation
of adipose tissue differentiation detected with GSEA method was a new finding. Up-regulation of
adipose tissue differentiation is in line with the observation of increased postprandial insulin
response found in Study I. In Study II, the RP diet showed general down-regulation of genes linked
to insulin signaling. On the other hand, GSEA analysis showed down-regulation of pathways
related to stress reactions, insulin signaling and energy metabolism. The down-regulation of
pathways in stress reaction is interesting because OWP diet seemed to produce stress, whereas
based on the GSEA analysis RP diet seemed to decrease the stress response (284).
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The fold changes in gene expression in SAT were moderate throughout the series of studies. This
was expected due to fact that the diets differed only with respect to the carbohydrate source for
about  half  of  the  daily  carbohydrate  intake.  Moreover,  the  study  subjects  did  not  lose  nor  gain
weight on average. In Study II, the mean changes in RP diet varied from 0.71- to 0.93-fold and in
OWP diet from 1.07- to 1.93-fold. The fold changes in other human microarray studies are
somewhat similar. Specifically, the effects of different energy-restricted diets on adipose tissue gene
expression in obese women were studied in 2005 (253). The diets resulted in weight losses of
7.5% of baseline body weight. However, fold change among these genes varied in the up-regulated
group between 1.10 and 1.46 and in the down-regulated group between 0.35 and 0.90, respectively.
A more recent weight reduction study conducted by Capel et al. (255) resulted fold changes from
0.62 to 1.25. Another reason for the moderate fold changes may be the fact that the most of the
changes in gene expression occurred already during the first weeks of the intervention.  Week 12
may represent a maintenance or “stable state” phase. More frequent adipose tissue sampling might
have been useful. However, due to ethical considerations this was not possible.
Considering dietary habits in Finland, subjects in the RP group probably had to change their diet
substantially less than subjects in the OWP diet group. Approximately 85% of Finnish men and
women include rye bread in their diet, and 25% of men and 22% of women use wheat bread (285).
6.1.5 The cell culture models
In the Study IV,  two cell  culture  models  were  used  to  study  the  role  of  IGFBP5 in  the  adipocyte
biology. Commercial Poietics® subcutaneous preadipocytes are precursor cells, isolated from
subcutaneous fat, that develop into adipocytes when fully differentiated and are characterized by
accumulation of intracellular triglycerides. Because cells used in this study were derived from one
obese individual without T2DM, interindividual variation cannot be excluded. On the other hand,
this cell model is appropriate when studying adipogenesis because the cells are not immortalized.
According to the recent literature, these cells are widely used (273,286).
Human Simpson-Golabi-Behmel Syndrome (SGBS) preadipocytes, originally derived from the
stromal fraction of subcutaneous adipose tissue of an infant with SGBS, are a cell strain with a high
capacity for adipose differentiation and thus represent an excellent tool for studying human fat cell
development (287). A number of studies have established that the pattern and time-course of gene
expression in SGBS cells during differentiation are comparable to the findings in human
preadipocytes in primary culture and also resemble the characteristics of rodent preadipocyte cell
lines (274,287,288). Differentiated SGBS cells also behave biochemically and functionally like
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human adipocytes differentiated in primary culture (287). In this study, SGBS cells were used to
examine the silencing of the gene expression of IGFBP5 in order to study the other transcriptional
changes of different genes expressed in SGBS cells
6.2 General discussion
6.2.1 Postprandial response to the study breads
During the 12-wk intervention period the test breads were consumed on a daily basis. It was
estimated that each individual had in all 200-300 servings (2-4 servings/day). It was hypothesized
that diets produced different insulin responses throughout the intervention period, which might
modulate gene expression of SAT. This hypothesis was based in part on earlier finding that insulin
acutely alters gene expression in WAT (40,131). Insulin stimulates glucose and FFA uptake in AT
and inhibits lipolysis (129,130). It also regulates important transcription factors in AT (132). In
other words, insulin has a crucial role in AT biology.
The postprandial events observed in Study I are  most  likely  to  be  the  underlying  reason  for  the
differences  seen  at  transcriptional  level.  The  oat  and  wheat  bread  (OW)  portion  produced
significantly higher postprandial insulin responses than rye bread independently of fiber. Despite the
difference in insulin response there was no significant difference in glucose response between the
OW and rye bread portions within the first 60 min of postprandial measurements. In other words,
less insulin was required for regulation of postprandial plasma glucose after rye bread portion than
after OW bread portion. This is a very intriguing finding because both high postprandial insulin and
high fasting insulin concentrations have been linked to the development of T2DM (289-291).
Moreover, worsening insulin resistance over time with compensatory hyperinsulinemia and
declining ß cell  function  is  critical  in  the  pathogenesis  of  T2DM  (292).  Theoretically,  diets  that
preserve ß cell function by improving insulin sensitivity and reducing postprandial glycemia or
insulinemia are likely to be useful in the prevention or treatment of metabolic diseases.
At the 90-min time point the glucose concentration started to drop faster after OW bread portion
than  it  did  after  rye  bread  portion.  The  obvious  explanation  for  this  steeper  drop  was  higher
postprandial insulin response of OW bread portion. High insulin concentration enhances the by
tissues glucose uptake and simultaneously decreases the blood glucose concentration. Decrease of
blood glucose under normal glucose values induces secretion of glucagon, cortisol, growth hormone
and adrenaline (293). In fact, there was a small increase in the postprandial adrenaline response
from 60 to 120 minutes after OW bread consumption. When the plasma glucose decreases under
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fasting  glucose  concentration  it  is  known  to  mobility  FFA  from  AT  (294).  A  clear  indication  of
FFA mobilization in this study was observed after OW bread portion as FFA concentration was
elevated at the 180 minutes time point. An increased late postprandial serum FFA level is known to
induce insulin resistance, a key element in pathogenesis of T2DM (295). Usually the elevation is
seen after 4 to 6 hours after consumption of high-glycemic meal (294). Thus, a longer follow-up
would have been appropriate to confirm the late postprandial effects of glycemia and nonesterified
FFA mobilization.
The postprandial events seen in Study I were similar to those observed in a previous study (224).
Whole kernel and endosperm rye bread produced lower postprandial insulin response than did white
bread, but there were no differences in glucose responses (224). It was concluded that the response
was probably due to bread structure; whole kernel and low-fiber endosperm rye bread has a more
dense matrix than white wheat bread (180). In the current study, both breads were high in fiber.
Half of the OW bread portion consisted of bread made of 60% whole meal oat flour and 40% wheat
flour and half in equal portions of commercial breads. Half of rye bread portion consisted of low-
fiber endosperm rye bread and half in equal portions of whole-meal breads. The differences
between the bread protein content or the amino acid profile also might have contributed in the
different postprandial responses (13.4% w/w of protein in OW bread portion vs. 6.8% w/w of
protein in rye bread portion). Plasma adrenalin concentrations decreased sharply with increases in
plasma glucose and insulin concentrations in the early postprandial period, but increased during the
mid-  to  late  postprandial  period  after  the  oat  and  wheat  bread  meal.  The  increase  in  plasma
adrenaline may be in response to the rapid decline in the concentrations of glucose, presumably as a
counterregulatory response to prevent hypoglycemia (296).
To  further  elucidate  the  effects  seen  in  this  postprandial  study,  it  is  possible  that  rye  bread
enhances the acute insulin response (AIR) as reported with high-fiber rye bread (180). Similarly, the
long-term rye bread and pasta diets increased early insulin secretion as measured by the
insulinogenic index in this study. Progressive deterioration of early insulin secretion is typical in the
transition from normal glucose tolerance to impaired glucose tolerance and further to T2DM (291).
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6.2.2 Effects of oat-wheat bread and potato diet
In Study I, the circulating cytokine (IL-1ȕ and IL-6) concentrations increased and gene expression
of  TNF-Į and  IL-10  receptor  Į were  up-regulated  in  SAT  in  response  to  the  OWP  diet.
Furthermore, the diet up-regulated genes related to stress, including inflammation and interleukin
cytokines, oxidative stress, and heat shock proteins (Study II) in human SAT.
The observation that OWP diet producing high insulin response induces the expression of genes
related to inflammation, metabolic stress and immune activation is a new finding. The most likely
physiological explanation for the pro-inflammatory effects may be the elevated insulin levels
followed by a transient drop in glycemia below fasting levels. Low glucose values activate certain
metabolic patterns, as discussed in chapter 6.2.1.
In line with the observations seen in this study, other studies have shown that hyperinsulinemia
(initiated by short-term acute hyperglycemia) may increase inflammation by increasing circulating
concentrations of radical oxygen species and proinflammatory cytokines, and may also activate the
NF-țB pathway in circulating mononuclear cells (297-300). Furthermore, studies have linked high
glycemic index foods to inflammation and the risk of T2DM (159,301).
The circulating concentration of cytokines such as IL-1ȕ and IL-6 are high in obesity (302) and
were also increased in Study I.  The up-regulation of IL-10 receptor-Į in response to OWP diet can
be interpreted as an anti-inflammatory response, possibly in compensation for the changes in
proinflammatory cytokines. IL-10 receptor-Į was also up-regulated in response to 8 weeks of
saturated fatty acid (SFA) diet, which also resulted in pro-inflammatory effects (256). Moreover IL-
6 is known to up-regulate IL-10 expression (303). In Study II, up-regulation of gene expression for
serum/glucocorticoid regulated kinase suggests activation of the glucocorticoid axis (304). It has
been demonstrated that activation of the pituitary-adrenal glucocorticoid axis may be involved in the
complex neuroendocrine dysregulation of the MetS (305). Up-regulation of heat shock proteins
indicates a response to stress such as oxidative stress and inflammation (306). Furthermore, in Study
II evidence was found for the activation of MAP kinases, which contributes to the inflammatory
response and oxidative stress (307).
It is evident that part of the pro-inflammatory effects seen in this study is due to activation of the
stromal vascular fraction of adipose tissue. A high level of co-ordination of inflammatory and
metabolic pathways is highlighted by the overlapping biology and function of macrophages and
adipocytes (145). For example, macrophages express many genes expressed in such as the
adipocyte/macrophage FABP4 and PPARȖ, whereas adipocytes express many cytokines such as
TNF-Į, IL-6, and MMPs (308, 309-311).
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In Study II, up-regulation of FABP5 was detected. Feeding a Western-type diet in mice induced a
16 to 22-fold increase in FABP5 within the first 2 weeks of the diet (312). The authors concluded
that FABP5 may have an important role in the Western-type diet. The activation of genes related to
cytokine-chemokine–mediated immunity in response to OWP diet is an interesting finding. In Study
II, CCL18 was up-regulated 1.72 fold. CD68(+) monocytes/macrophages are the main
CCL18/PARC-producing cell type in PBMCs (313). The representative inflammation-related genes
CCL2 (monocyte chemoattractant protein-1) and CCL3 (macrophage inflammatory protein 1-Į)
were highly up-regulated in very obese (mean BMI 55 kg/m2 Pima Indians compared to non-obese
individuals (mean BMI 25 kg/m2) (247). Van Dijk et al. (256) demonstrated that CCL4 was
significantly up-regulated after an 8-week SFA diet along with inflammation. Furthermore, it has
been demonstrated that monocytes can be activated by both high-and low-glycemic load (GL)
meals in healthy overweight women (314). However, intervention studies on the inflammatory
effects of chronic consumption of diets with a high GL, particularly in subjects who are at increased
risk of metabolic disease, have not been conducted. Nevertheless, it is possible that in individuals
with MetS, the inflammatory changes are more evident than in individuals with normal glucose
homeostasis.
Re-analysis of the gene expression data using GSEA-methodology revealed that gene sets related
to stress reactions were up-regulated in the OWP diet group thus, supporting the findings of this
thesis (284). The increase of multiple lysoposphatidylcholine species (lysoPCs) in the OWP diet
group was found. LysoPCs are reactive lipid by-products that act as a major bioactive lipid
component of oxidized LDL, and may be responsible for many of the inflammatory effects of
oxidized LDL (315,316). The study by Lankinen et al. (284) brings supportive evidence to the pro-
inflammatory effects of prolonged OWP diet detected in Studies I and II.
As a summary, a high insulin response diet could predispose to inflammation, insulin resistance
and an increased risk of T2DM (171). The findings of this study give new information on how OWP
diet may be linked to increased metabolic stress, inflammation and insulin resistance in individuals
of MetS. Many of the events occurring in response to OWP diet are similar observed in progression
of obesity and may be the biomarkers of worsening insulin resistance.
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6.2.3 Effects of rye bread and pasta diet
In the Study II, general down-regulation of gene expression in the RP diet producing low
insulinemic responses was detected in human SAT. The genes related to insulin signaling and
apoptosis were down-regulated. The genes closely linked to the insulin signaling pathway were
IGFBP5 and insulin receptor (INSR). The most obvious explanation for the down-regulation of
insulin related genes would be the diminished overall postprandial insulin secretion shown in the
Study I.  Moreover, RP diet improved insulinogenic index in 12 weeks.
One of the genes responding to the RP diet, IGFBP5, modulates the effects of IGF-I and IGF-II,
but its other functions in human AT are unknown (317). IGF-I induces the differentiation of
preadipocytes, and therefore its binding proteins are of great interest (318). Therefore, IGFBP5 was
further investigated, as discussed in chapter 6.2.4. Moreover, the RP diet also down-regulated the
gene encoding the insulin receptor. There is a mouse study demonstrating that selective knockout of
insulin receptor in the AT improves lipid and glucose homeostasis (319). It is possible that repeated
lower postprandial insulin responses may contribute to the down-regulation of adipose tissue
expression of the insulin receptor through decreased demand for receptor binding.
The adipocyte cell size decreased significantly during the 12-wk RP diet, whereas there was no
change in body weight. The observed down-regulation of hormone sensitive lipase (LIPE) in the RP
diet group may occur as a consequence of the decrease in adipocyte cell size. Indeed, some studies
have reported a close association of adipocyte cell size with LIPE mRNA expression (320). LIPE is
the  rate-limiting  enzyme of  lipolysis  and  one  of  a  key  enzymes  in  the  release  of  fatty  acids  from
AT. FFAs induce insulin resistance in adipose tissue. Therefore, down-regulation of LIPE and
decreased adipocyte cell size may suggest both decreased lipolysis and enhanced insulin sensitivity
in SAT (321). There is also a mouse study where LIPE-deficient mice were resistant to genetic- or
diet-induced obesity (322). Moreover, absence of LIPE inhibits obesity and adipogenesis in Lep
ob/ob mice (323). Because a significant correlation between LIPE gene expression and adipocyte
cell size was not detected, this study did not bring new information of the relation of adipocyte size
and hormone-sensitive lipase expression. On the other hand, the data are from mRNA-level, and the
protein levels of LIPE are unknown.
The transcription factor TCF7L2 was significantly down-regulated after the RP diet. This is a very
interesting finding because during the publication process of the Study II, TCF7L2 was found to be
the strongest known genetic predictor of T2DM (260,276,324). Simple sequence repeats within
intron 3 of TCF7L2 occurs with increased frequency of T2DM, which contributes to an estimated
population attributable risk of 21% (276). Although the mechanisms by which common variants in
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the TCF7L2 gene increase risk of type 2 diabetes have not been fully elucidated, this transcriptional
regulator was shown to be involved in stimulating the proliferation of pancreatic ȕ cells and the
production of the incretin hormone (glucagon-like peptide-1) in intestinal endocrine L cells (325-
327). TCF7L2 has several tissue-specific alternative splicing variants among fat depots and
pancreas (328-330). It is plausible that changes observed in SAT gene expression of TCF7L2 might
have been influenced by diminished postprandial insulin secretion in the pancreas.
6.2.4 Studies on IGFBP5 gene
IGFBPs play a crucial role in modifying the activity of insulin-like growth factors (IGF) in various
cell types (331,332). In addition, some of the family members, namely IGFBP5 and IGFBP3, have
direct IGF-independent effects on cellular growth and apoptosis (331,333). Study II showed that a
12-week RP diet producing low insulin response resulted in decreased expression of IGFBP5
mRNA in human SAT. According to the findings in this study, the IGFBP5 gene is highly
expressed in human white adipose tissue (WAT). Three IGFBP5 SNPs (rs9341234, rs3276 and
rs11575134) were strongly associated with serum adiponectin concentrations in men with IGT.
Moreover, a correlation between IGFBP5 and adiponectin gene expression in SAT in all subjects
and in women with metabolic syndrome participating in FUNGENUT and GENOBIN was found.
Study IV revealed that IGFBP5 is upregulated during the adipogenesis. Moreover, IGFBP5 protein
was found to upregulate the gene expression of ADIPOQ in cultured primary adipocytes. Silencing
of IGFBP5 gene did not affect the gene expression of ADIPOQ in SGBS cells. Thus, IGFBP5 may
not be directly linked to the regulation of adiponectin expression in subcutaneous adipocytes. Other
evidence  presented  shows  that  IGFBP5  may  regulate  some  other  adipocyte-specific  pathways.
Taken together, the action of IGFBP5 is specifically related to the AT function and may also be
related to the development MetS and T2DM.
 Other IGFBPs namely IGFBP1 and IGFBP3 have responded postprandially to the glycemic load
of the diet (334). Specifically, the change in serum IGFBP3 concentration was significantly higher
after the low-glycemic index meal than after the high-glycemic index meal. In contrast, serum
IGFBP1 declined markedly after both meals, but the mean change at 4 h was significantly more
prolonged after the low-glycemic index meal than after the high-glycemic index meal (334). These
studies indicate that the IGF–IGFBP signaling pathway could be a target for nutritional factors that
modulate glucose metabolism and insulin action. In the light of the evidence for IGFBP1 and
IGFBP3, the postprandial response of IGFBP5 would be of interest to study in the future.
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IGFBP5 and its genetic variation are associated with circulating adiponectin concentrations in
persons with impairments in glucose metabolism. In Study III, the gender-specific association
between IGFBP5 and adiponectin was demonstrated both at the gene and mRNA level. Three
IGFBP5 SNPs (rs9341234, rs3276 and rs11575134) were strongly associated with serum
adiponectin concentrations in men with IGT. Moreover, a correlation between IGFBP5 and
adiponectin gene expression in SAT in all subjects and in women with metabolic syndrome
participating in FUNGENUT and GENOBIN was found. The exact reason for differences between
genders between the genetic and transcriptomic level is difficult to elaborate. However, a gender-
specific link between the genetic variation of IGFBP5 and circulating adiponectin concentration is a
novel finding. IGFBP1, sex hormone-binding globulin and C-peptide have a strong and independent
association with adiponectin (335).  This interaction may suggest that also IGFBP5 mediates
gender-specific effects on adiponectin production (or vice versa) or secretion through interaction
with sex hormones. The gender-specific differences may also be explained by the different
distribution of AT depots between genders (336,337). There was no effect on ADIPOQ gene
expression when IGFBP5 was silenced in SGBS-cells with SiRNA-technique (Study IV). However,
IGFBP5 protein was found to up-regulate the gene expression of ADIPOQ in cultured primary
adipocytes. This finding indicates that IGFBP5 may regulate some adipocyte specific pathways.
However, adiponectin protein did not modulate the IGFBP5 gene  expression  in  the  same  cell
culture (Figure 12). Nevertheless, there might other non-direct links which connects adiponectin to
IGFBP5 in AT.
 In Study IV, IGFBP5 was up-regulated in the adipogenesis, and IGFBP3 was down-regulated cells
derived from subcutaneous AT. In the visceral AT of obese subjects, IGFBP5 was reported to be
downregulated, whereas IGFBP3 was upregulated (241). In insulin resistance, IGFBP3 has also
been up-regulated in VAT, but not in SAT (338).  It is possible that IGFBP5, like its family
members, may have certain adipose tissue depot-specific functions (339).  The upregulation of
IGFBP5 in adipocytes goes in line with other cell lineages, such as osteoblasts and myoblasts
(340,341). There is evidence that IGFBP5 may  act  as  a  growth  factor  (342).  Moreover, IGFBP5
regulates muscle cell differentiation by binding to IGF-II and switching on the IGF-II auto-
regulation loop (343). In addition to different cell types, IGFBP5 is up-regulated in some cancers,
such as breast cancer (317,344). Based on a recent in silico screening approach, IGFBP5 has been
demonstrated to be a primary PPARȖ target gene (345).  Both IGFBP5 and IGFBP3 form ternary
complexes with IGF-I and ALS, thus modulating the half-life of IGF-I (346). The overexpression of
IGFBP5 has resulted in a massive reduction in serum IGFBP3 protein (317). In addition, knock-out
of IGFBP5 increased IGFBP3 serum levels, indicating that IGFBP3 is likely up-regulated to
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compensate for the  loss  of IGFBP5 (347). Thus, there seems to be an equilibrium between the
IGFBP5 and IGFBP3 in the formation of IGF complexes.
 In Study IV, treatment of adipocytes with these adipokines resulted in a significant down-
regulation of IGFBP5. Enlarged, insulin-resistant adipocytes and macrophages secrete large
amounts of TNFĮ, IL-1ȕ and IL-10 (111,348). It has been shown in this thesis that during the RP
diet there was both a decrease in the plasma concentration of IL-1 ȕ and down-regulation of
IGFBP5. “Healthy” adipocyte may compensate for this change by producing less IGFBP, thus
allowing more free IGF to activate the insulin receptor pathway. There is evidence that IGF-1
contributes to long-term glucose homeostasis, whereas insulin is the key short term regulator of
glucose homeostasis (349).
 In Study IV,  it  was  shown  that  the  IGFBP5  protein  was  localized  in  the  close  vicinity  of
adipocytes. This finding indicates that IGFBP5 is also produced by adipocytes. Moreover, it has
been reported that IGFBP5 binds to heparin and may have a cell surface binding site (350). This
finding goes in line with the observation in Study IV of localization of IGFBP5 protein on the cell
membrane or in the extracellular matrix. IGFBP5 also binds into glycosaminglycans located on the
cell surface (351).
 Significant down-regulation of TCF7L2 was  found  when IGFBP5 was silenced in SGBS cells.
Both TCF7L2 and IGFBP5 were also down-regulated (0.85 and 0.87 fold, respectively) in the RP
diet  (Study  II).  TCF7L2  is  a  critical  component  of  Wnt  signaling  action,  and  genetic  variants  of
TCF7L2 predict the development of T2DM (260). There is a recent paper showing that IGFBP4 is
an inhibitor of Wnt/ȕ-catenin signaling pathway, whereas IGFBP5 shows no such inhibitory action
(352). Reichling et al. (353) have shown that IGFBP5 may be a target gene in Wnt signaling.
Further functional studies are needed to understand the mechanistic link between IGFBP5, TCF7L2
and Wnt signaling. However, this finding suggests that IGFBP5 may contribute to the development
of MetS and T2DM.
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6.3 Concluding remarks
The studies in this thesis investigated the biological effects of two cereal-based diets (rye and oat-
wheat bread) in persons with MetS. The breads produced markedly differential postprandial
responses. Specifically, insulin responses varied markedly after the ingestion of the breads. The
ingestion of rye bread reduced postprandial insulin requirements and improved first-phase insulin
secretion  in  OGTT.  Both  of  these  factors  are  associated  with  effective  glucose  metabolism and  a
decreased risk of T2DM. Genes regulating insulin signaling and apoptosis were down-regulated
during the low insulin response diet, and genes related to inflammation were up-regulated during
the high insulin response diet. One of the genes that down-regulated during the RP diet was
IGFBP5. This gene was further studied using candidate gene approach in DPS and METSIM
populations. Moreover, the function of IGFBP5 in adipocyte biology was studied using in vitro
methodology.
Study II is the first human study in which the effects of diet intervention without the aim of weight
loss on gene expression of AT was investigated using microarray analysis. The microarray approach
even with its known limitations appeared to be an excellent hypothesis generator for finding new
candidate genes in the clinical study setting. Based on the microarray analysis, IGFBP5 was chosen
to be further studied with more traditional methodology. Using the traditional candidate gene
approach genes like IGFBP5 might have been neglected. Genotyping of populations with
impairments in glucose tolerance with eight IGFBP5 SNPs showed a gender-specific association
with adiponectin. Adiponectin is one of the most studied adipokines, related to obesity and MetS.
The data provided in this study clearly suggest that IGFBP5 has an active role in AT. Many genes
involved in adipocyte biology responded to IGFBP5.  However,  more functional studies should be
conducted to elucidate the specific action of IGFBP5 in white adipose tissue. It would be interesting
to apply microarray methodology in an experiment comparing the gene expression responses in
adipocytes with normal IGFBP5 gene expression and in those with silenced gene expression. This
approach would most likely to unravel new unexpected genes for further study.
Study II demonstrated that both IGFBP5 and TCF7L2 were down-regulated in response to the diet
producing a low insulin response. Moreover, the Study IV showed that when IGFBP5 was silenced
with SiRNA methodology, TCF7L2 was also down-regulated. A recent study found out that the
expression of TCF7L2 was related to genotype and metabolic measures in human islets (325). A
five-fold increased expression of TCF7L2 was found in human islets of patients with T2DM, and
this was most pronounced in rs7903146-TT genotype carriers. Overexpression of TCF7L2 in human
islets reduced glucose-stimulated insulin secretion (325). A previous study suggests that long-term
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ingestion of high-fiber rye bread may enhance insulin secretion as assessed with FSIGT, possibly
indicating the recovery of ȕ-cell function (180). Follow-up studies are necessary to elucidate
possible mechanisms linking IGFBP5 and TCF7L2.
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7 SUMMARY
The results can be summarized as follows:
Study I:
The postprandial insulin response was lower after the rye bread meal than after the oat and wheat
bread meal. Moreover, plasma glucose concentrations dropped more rapidly under the fasting level
after the OW bread portion than after the rye bread portion.  Twelve weeks of consumption of the
OWP diet up-regulated inflammatory markers in mRNA of AT and increased circulating cytokine
concentrations in persons with MetS. These pro-inflammatory changes may increase the risk of
developing T2DM.
Study II:
A 12-wk diet intervention with RP diet down-regulated genes linked to insulin signaling and
apoptosis. IGFBP5 was linked to insulin signaling and significantly down-regulated after RP-diet.
Moreover, adipocyte cell size was diminished and the first-phase insulin secretion improved.  In
contrast, the intervention with the OWP diet up-regulated genes linked to stress, cytokine-
chemokine-mediated immunity and the interleukin pathway. The body weight was unchanged in
both groups.
Study III:
Three IGFBP5 markers (rs9341234, rs3276 and rs11575134) were significantly associated with
circulating adiponectin concentrations in men with impaired glucose tolerance. Furthermore,
mRNA expression  studies  of  SAT showed that  mRNA concentrations  of IGFBP5 correlated with
adiponectin  concentrations  in  all  subjects  and  in  women.  None  of  the IGFBP5 SNPs were
associated with T2DM. IGFBP5 may have a gender-specific association with adiponectin, which
may modulate the development of MetS.
Study IV:
IGFBP5 was up-regulated during adipogenesis, and the protein was localized  in WAT. Several
genes involved in adipocyte biology were responding to silencing of IGFBP5. Moreover,
adipocytokines secreted by adipose tissue regulated IGFBP5 gene expression. The addition of
IGFBP5 protein up-regulated the adiponectin gene expression in vitro. These data provide new
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information about the role of IGFBP5 in adipocyte biology and strengthen a potential link between
IGFBP5 and metabolic diseases.
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